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Experimental Section/Chemistry 
General Remarks  
Solvents were purified and dried by standard methods. Flash column chromatography was 
performed using silica gel (40 – 63 mm, Merck). TLC analyses were performed by means of 
Merck Kieselgel 60 F254 (0.25 mm) Plates. Visualization was accomplished with UV light (254 nm) 
and/or an aqueous alkaline KMnO4 solution, followed by heating. Melting points are 
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uncorrected. NMR spectra were recorded in CDCl3 on either a Varian Mercury Plus 300 (300 
MHz for 1H, 75 MHz for 13C) or Varian Unity Inova 600 (600 MHz for 1H, 151 MHz for 13C) 
spectrometer. Chemical shifts (δ) are quoted in ppm and are referenced to TMS as internal 
standard. Elemental analyses were run with a FISONS EA1108 instrument. Optical rotations 
were measured with a JASCO P-1020 polarimeter with a water-jacketed 10.000 cm cell at a 
wavelength of the sodium D line (λ=589 nm), []D values are given in 10
-1 deg.cm2.g-1. FTIR 
spectra were obtained on a Nicolet 5700 spectrometer (Thermo Electron) equipped with a 
Smart Orbit (diamond crystal ATR) accessory, using the reflectance technique (4000–400 cm–1). 
HPLC was carried out using a PU-4015/PU-4021 PYE UNICAM HPLC system, using C18 5 μm 
reverse phase column and a mixture acetonitrile/water/Et3N from 400:600:15 to 100:900:15, pH 
adjusted to 2.9-3.5 by H3PO4. Detector PU-4021 was set in SUM ABS mode, λ = 210-310 nm. 
High-resolution mass spectra (HRMS) were recorded on a Thermo Scientific Orbitrap Velos mass 
spectrometer with a heated electrospray ionisation (HESI) source. The mass spectrometer was 
operated with full scan (50–2000 amu) in positive or negative FT mode (at a resolution of 
100000). The analyte was dissolved in MeOH and infused via syringe pump at a rate of 5 
mL/min. The heated capillary was maintained at 275 °C with a source heater temperature of 50 
°C, and the sheath, auxiliary and sweep gases were at 10, 5 and 0 units, respectively. The source 
voltage was set to 3.5 kV. (R)-1-Phenylethylamine, ChiPros 99+%, ee 99+% from Alfa Aesar, was 
used for the preparation of oxoamino acids 16A-C using our previously published CIAT 
applications.   
General procedure for (2R)-4-Aryl-4-oxo-2-{[(1R)-1-phenylethyl]amino}-butanoic acids 16A–C  
To the solution of corresponding aroylacrylic acids in methanol, (R)-1-phenylethylamine was 
added under stirring. The mixture was stirred at 25 °C for 4 days in the dark. The course of the 
CIAT process was monitored by HPLC. HPLC conditions: Luna 5 m, Phenyl-hexyl column  
250x4.6 mm (Phenomenex), eluent: acetonitrile/water/TEA/phosphoric acid = 200:800:8:4, flow 
rate 1.2 mL/min, detection UV 210 nm, retention time: (1´R,2R)-16A, 27.5 min; (1´R,2S)-16A, 
29.1 min; (1´R,2R)-16B, 26.8 min; (1´R,2S)-16B, 28.6 min; (1´R,2R)-16C, 23.3 min; (1´R,2S)-16C, 
24.9 min. The precipitate was filtered off, washed with methanol and ether, and dried under 
reduced pressure to give the corresponding adduct as a white powder with d.r. >97:3. Small 
quantity of diastereommerically pure crystals has been obtained by crystallization from the 
acetonitrile–water mixture. 
(2R)-4-(3-bromophenyl-4-oxo-2-{[(1R)-1-phenylethyl]amino}-butanoic acid (16A). This product 
was prepared according to the general procedure starting from the (E)-4-(3-bromophenyl)-4-
oxobutenoic acid (20 g, 78.4 mmol) and (R)-1-phenylethanamine (10.5 g, 86.3 mmol) in 
methanol (500 mL); the compound 16A (20.6 g, 70 %, dr 98 :2) was obtained as a white solid; 
mp 172-175 °C; []D
20 = –63.0 (c 0.10, MeOH:1M HCl = 3:1); 1H NMR (300 MHz, acetone-d6/DCl): 
δ  = 7.86-8.03 (d, 2H, J = 8.6, H-Ar); 7.56-7.78 (m, 4H,  H-Ar); 7.35-7.52 (m, 3H, H-Ar); 4.84 (q, 1H, 
J = 6.8, H-1´); 4.12 (t, 1H, J = 5.6 Hz, H-2); 3.93 (d, 2H, J = 5.5 Hz, H-3); 1.83 (d, 3H, J = 6.8 Hz, H-
2´) ; 13C NMR (75 MHz, acetone-d6/DCl): δ = 196.4 (C-4); 170.6 (C-1); 137.5, 136.3, 131.9, 131.2, 
131.0, 130.1, 129.9 (C-Ar); 60.5, 54.6 (C-2, C-1´); 40.6 (C-3); 21.7 (C-2´); IR (ATR): 2979, 2850, 
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1695, 1626, 1586, 1563, 1380, 1246, 1069, 987, 809, 698 cm-1. Anal. calcd for C18H18BrNO3: C 
57.47, H 4.82, N 3.72; found C 57.61, H 4.83, N 3.64. 
(2R)-4-(4-bromophenyl-4-oxo-2-{[(1R)-1-phenylethyl]amino}-butanoic acid (16B). Starting 
from the (E)-4-(4-bromophenyl)-4-oxobutenoic acid (4.7 g, 18.4 mmol) and (R)-1-
phenylethanamine (2.7 g, 22.0 mmol) in methanol (100 mL); the compound 16A (4.8 g, 69 %, dr 
99 :1) was obtained as a white solid; mp 187-189 °C; []D
20 = - 42.1 (c 0.70, MeOH:1M HCl = 3:1); 
1H NMR (300 MHz, acetone-d6/DCl): δ  = 7.82-7.89 (m, 2H, H-Ar); 7.61-7.70 (m, 4H, H-Ar); 7.35-
7.48 (m, 3H, H-Ar); 4.83 (q, 1H, J = 6.9 Hz, H-1´); 4.10 (t, 1H, J = 5.3 Hz, H-2); 3.89 (d, 2H, J = 5.4 
Hz, H-3); 1.80 (d, 3H, J = 6.9 Hz, H-2´); 13C NMR (75 MHz, acetone-d6/DCl): δ  = 196.3 (C-4); 170.3 
(C-1); 137.1, 136.0, 133.4, 131.7, 131.1, 130.9, 129.9, 129.8 (C-Ar); 60.4, 54.4 (C-2, C-1´); 40.3 (C-
3); 21.5 (C-2´); IR (KBr): 3027, 2983, 2851, 1697, 1631, 1606, 1587, 1478, 1383, 1354, 1275, 
1248, 1207, 988, 760, 700 cm-1. Anal. calcd for C18H18BrNO3: C 57.47, H 4.82, N 3.72; found C 
57.73 H 4.87, N 3.44. 
(2R)-4-(5-bromothiophene-2-yl)-4-oxo-2-{[(1R)-1-phenylethyl]amino}-butanoic acid (16C). 
Starting from the (E)-4-(5-bromothiophene-2-yl)-4-oxobutenoic acid (1.84 g, 7.1 mmol) and (R)-
1-phenylethanamine (1.03 g, 8.5 mmol) in methanol (20 mL); the compound 16C (2.0 g, 74 %, dr 
99:1) was obtained as a white solid; mp 175-178 °C; []D
20 = - 46.1 (c 0.80, MeOH:1M HCl = 3:1);  
1H NMR (300 MHz, acetone-d6/DCl): δ  = 7.80 (d, 1H, J = 4.1 Hz, H-Het); 7.64-7.68 (m, 1H, H-Ar, 
1H, H-Het); 7.38-7.47 (m, 4H, H-Ar); 4.82 (q, 1H, J = 6.7 Hz, H-1´); 4.06 (t, 1H, J = 5.5 Hz, H-2); 
3.85 (d, 2H, J = 5.5 Hz, H-3); 1.82 (d, 3H, J = 6.8 Hz, H-2´); 13C NMR (75 MHz, acetone-d6/DCl):  = 
188.8 (C-4); 170.0 (C-1); 137.1, 136.5, 134.0, 131.2, 130.9, 130.0, 124.4 (C-Ar, C-Het); 60.4, 54.3 
(C-2, C-1´); 39.9 (C-3); 21.5 (C-2´); IR (KBr): 2988, 2840, 1696, 1623, 1588, 1559, 1320, 1296, 
1069, 1033, 987, 700 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C16H17BrNO3S: 382.01070; found: 
382.01050. 
General procedure for DCC-mediated lactonization  
A suspension of γ-oxo-α-aminoacid (16A-C, 10 mmol) and MnCl2.4H2O (2 mmol) in MeOH (120 
mL) was cooled to 0 °C and NaBH4 (40 mmol) was added in small portions. The mixture was 
stirred at 0 °C until HPLC analysis had shown complete consumption of starting materials 
(typical 3–4 hours). The solution was evaporated in vacuo. To a residue was added water (50 
mL) and 10% K2CO3 (100 mL). The resulting mixture was stirred for 10 minutes and the insoluble 
solid was filtered off. The pH of the filtrate was adjusted to 6.5 using 4N HCl. The resulting syn-
hydroxy acid was filtered off, washed with water (3 x 30 mL), diethyl ether (30 mL) and dried 
under the diminished pressure at 60 °C. To the well-homogenized (ultrasound) suspension of 
syn-hydroxy acid in dry dichloromethane (50 mL), DCC (11 mmol) was added in one portion. The 
mixture was stirred for 20 h. The suspension was concentrated to 1/3 of volume and insoluble 
solids were filtered off and filtrated was concentrated under reduced pressure. Filtrate was 
concentrated under reduced pressure and the crude product was purified by flash column 
chromatography to yield the trans-lactone 17A-C.  
(3R,5S)-5-(3-Bromophenyl)-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-2(3H)-one (trans-17A). 
This product was prepared according to the general procedure; compound trans-17A (2.413 g, 
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67%) was obtained as yellowish oil after purification by flash column chromatography, eluting 
with hexane/EtOAc (5:1 up to 3:1). TLC: Rf = 0.25 (hexane/EtOAc 3:1, UV, KMnO4); []D
20 = +97 
(c 0.21, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.44-7.39 (m, 1H, H-Ar); 7.36-7.17 (m, 7H, H-Ar); 
7.11-7.06 (m, 1H, H-Ar); 5.48 (dd, 1H, J = 4.0, 7.9 Hz, H-5); 4.03 (q, 1H, J = 6.6 Hz, H-1´); 3.46 (t, 
1H, J = 8.1 Hz, H-3); 2.22 (td, 1H, J = 8.1, 13.1 Hz, H-4A); 2.01 (ddd, 1H, J = 4.0, 8.0, 13.1 Hz, H-
4B); 1.39 (d, 3H, J = 6.6 Hz, H-2´); 13C NMR (75 MHz, CDCl3):  = 176.9 (C-2); 144.7, 141.6, 131.3, 
130.3, 128.5, 128.0, 127.4, 126.9, 123.5, 122.9 (C-Ar); 77.4 (C-5); 57.7, 54.5 (C-3, C-1´); 38.6 (C-
4); 24.6 (C-2´); IR (ATR): 3355, 2977, 2853, 1771, 1448, 1255, 1135, 1019, 955, 732, 699, 500  
cm-1. HRMS (ESI): m/z [M + H]+ calcd for C18H19BrNO2: 360.05992; found: 360.05920. 
3R,5S)-5-(4-Bromophenyl)-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-2(3H)-one (trans-17B). 
This product was prepared according to the general procedure; compound trans-17B (1.729 g, 
48%) was obtained as a white solid after purification by flash column chromatography, eluting 
with hexane/EtOAc (3:1). TLC: Rf = 0.26 (hexane/EtOAc 3:1, UV, KMnO4); Mp = 90-92 °C 
(hexane/Et2O); []D
20 = +114 (c 0.63, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.48-7.43 (m, 2H, H-
Ar); 7.36-7.23 (m, 5H, H-Ar); 7.04 (d, 2H, J = 8.4 Hz, H-Ar); 5.47 (dd, 1H, J = 4.0, 7.9 Hz, H-5); 4.03 
(q, 1H, J = 6.6 Hz, H-1´); 3.43 (t, 1H, J = 8.1 Hz, H-3); 2.22 (td, 1H, J = 8.1, 13.1 Hz, H-4A); 1.99 
(ddd, 1H, J = 4.0, 8.0, 13.0 Hz, H-4B); 1.38 (d, 3H, J = 6.6 Hz, H-2´); 13C NMR (75 MHz, CDCl3):  = 
177.0 (C-2); 144.7, 138.4, 131.9, 128.5, 127.4, 126.9, 126.6, 122.6 (C-Ar); 77.7 (C-5); 57.8, 54.6 
(C-3, C-1´); 38.7 (C-4); 24.7 (C-2´); IR (ATR): 3346, 2970, 1774, 1489, 1448, 1254, 1139, 1009, 
958, 764, 702, 497 cm-1. Anal. Calcd. For C18H18BrNO2: C 60.01, H 5.04, N 3.89. Found: C 60.21, H 
5.08, N 3.92. 
(3R,5S)-5-(5-Bromo-thiophen-2-yl)-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-2(3H)-one 
(trans-17C). This product was prepared according to the general procedure; compound trans-
17C (2.307 g, 63%) was obtained as pale brown oil after purification by flash column 
chromatography, eluting with hexane/EtOAc (5:1 up to 3:1). TLC: Rf = 0.28 (hexane/EtOAc 3:1, 
UV, KMnO4); []D
20 = +115 (c 0.31, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.38-7.23 (m, 5H, H-Ar); 
6.89 (d, 1H, J = 3.8, H-Het); 6.65 (d, 1H, J = 3.8 Hz, H-Het); 5.57 (dd, 1H, J = 3.4, 7.7 Hz, H-5); 4.04 
(q, 1H, J = 6.6 Hz, H-1´); 3.56 (t, 1H, J = 8.5 Hz, H-3); 2.18 (ddd, 1H, J = 7.8, 9.0, 13.2 Hz, H-4A); 
2.07 (ddd, 1H, J = 3.4, 8.1, 13.2 Hz, H-4B); 1.41 (d, 3H, J = 6.6 Hz, H-2´); 13C NMR (75 MHz, CDCl3): 
 = 176.4 (C-2); 144.7, 143.4, 129.8, 128.6, 127.5, 127.0, 125.7, 113.1 (C-Ar, C-Het); 74.5 (C-5); 
58.1, 55.1 (C-3, C-1´); 38.3 (C-4); 24.5 (C-2´); IR (ATR): 3332, 2958, 1765, 1441, 1203, 1112, 965, 
801, 760, 698, 550 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C16H17BrNO2S: 366.01634; found: 
366.01709. 
General procedure for acid catalyzed cis-lactonization  
Sodium borohydride (40 mmol) was added in small portions to the finely homogenized 
suspension of the oxoamino acid (16A-c, 20 mmol) in MeOH (100 mL) over 1 hour. When the 
reduction was complete (3-5 hours, HPLC monitoring), MeOH was evaporated under reduced 
pressure. The remaining mixture fo the both diastereomers of hydroxyamino acids (d.r.~2:1) 
was triturated with 8 M hydrochlorid acid (100 mL) and treated with ultrasound bath (15 min). 
Thereafter the reaction mixture was stirred at 40 °C for additional 24 hours. The course of CIAT 
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process was monitored by HPLC. HPLC conditions: Luna 5 m, Phenyl-hexyl column  250x4.6 mm 
(Phenomenex), eluent: acetonitrile/water/TEA/85 % phosphoric acid = 333:666:5:5, flow rate 
1.2 mL/min, detection UV 210 nm, retention time: cis-18A, 11.3 min; trans-18A, 12.4 min; cis-
18B, 10.7 min; trans-18B, 13.8 min; cis-18C, 12.2 min; trans-18C, 13.5 min. The crystalline solid 
was filtered off, washed with cold 1% hydrochloric acid and ether. The raw (18A-C).HCl was 
triturated with 200 mL of 5% potassium carbonate solution and extracted with Et2O (3 × 100 
mL). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced 
pressure and the crude product was purified by crystallization (hexane/Et2O) to yield the desired 
cis-lactone 18A-C. 
(3R,5R)-5-(3-Bromophenyl)-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-2(3H)-one (cis-18A). 
This product was prepared according to the general procedure; compound cis-18A (5.044 g, 
70%) was obtained as a white solid after purification by crystallization. TLC: Rf = 0.30 
(hexane/EtOAc 3:1, UV, KMnO4); Mp = 86-89 °C (hexane/Et2O); []D
20 = -25 (c 0.35, CHCl3); 
1H 
NMR (300 MHz, CDCl3):  = 7.45-7.15 (m, 9H, H-Ar); 5.09 (dd, 1H, J = 5.3, 11.1 Hz, H-5); 4.13 (q, 
1H, J = 6.5 Hz, H-1´); 3.59 (dd, 1H, J = 7.9, 11.9 Hz, H-3); 2.28 (ddd, 1H, J = 5.3, 7.9, 13.0 Hz, H-
4A); 1.80-1.68 (m, 1H, H-4B); 1.41 (d, 3H, J = 6.5 Hz, H-2´); 13C NMR (75 MHz, CDCl3):  = 177.0 
(C-2); 144.7, 140.6, 131.7, 130.3, 128.7, 128.5, 127.4, 127.0, 124.1, 122.8 (C-Ar); 77.4 (C-5); 58.5, 
57.6 (C-3, C-1´); 40.9 (C-4); 24.8 (C-2´); IR (ATR): 3325, 2965, 1777, 1499, 1312, 1247, 1168, 
1008, 766, 700, 507 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C18H19BrNO2: 360.05937; found: 
360.05927. 
 (3R,5R)-5-(4-Bromophenyl)-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-2(3H)-one (cis-18B). 
This product was prepared according to the general procedure; compound cis-18B (4.755 g, 
66%) was obtained as a white solid after purification by crystallization. TLC: Rf = 0.30 
(hexane/EtOAc 3:1, UV, KMnO4); Mp = 107-109 °C (hexane/Et2O); []D
20 = -34 (c 0.25, CHCl3); 
1H 
NMR (300 MHz, CDCl3):  = 7.47 (d, 2H, J = 8.2 Hz, H-Ar); 7.38-7.20 (m, 5H, H-Ar); 7.12 (d, 2H, J = 
8.4 Hz, H-Ar); 5.09 (dd, 1H, J = 5.3, 11.1 Hz, H-5); 4.13 (q, 1H, J = 6.5 Hz, H-1´); 3.59 (dd, 1H, J = 
7.9, 11.9 Hz, H-3); 2.26 (ddd, 1H, J = 5.3, 7.8, 12.9 Hz, H-4A); 1.72 („dd“, 1H, J = 11.4, 12.0 Hz, H-
4B); 1.41 (d, 3H, J = 6.5 Hz, H-2´); 13C NMR (75 MHz, CDCl3):  = 177.1 (C-2); 144.8, 137.3, 131.9, 
128.5, 127.5, 127.3, 122.6 (C-Ar); 77.7 (C-5); 58.6, 57.7 (C-3, C-1´); 40.9 (C-4); 24.8 (C-2´); IR 
(ATR): 3321, 2968, 1780, 1491, 1314, 1170, 1001, 818, 764, 698, 505 cm-1. Anal. Calcd. For 
C18H18BrNO2: C 60.01, H 5.04, N 3.89. Found:C 60.20, H 5.24, N 3.81. 
(3R,5R)-5-(5-Bromo-thiophen-2-yl)-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-2(3H)-one (cis-
18C). This product was prepared according to the general procedure; compound cis-18C (5.201 
g, 71%) was obtained as a white solid after purification by crystallization. TLC: Rf = 0.33 
(hexane/EtOAc 3:1, UV, KMnO4); Mp = 67-68 °C (hexane/Et2O); []D
20 = -132 (c 0.5, CHCl3); 
1H 
NMR (300 MHz, CDCl3):  = 7.40-7.22 (m, 5H, H-Ar); 6.91 (d, 1H, J = 3.8 Hz, H-Het); 6.77 (d, 1H, J 
= 3.8 Hz, H-Het); 5.24 (dd, 1H, J = 5.2, 11.1 Hz, H-5); 4.13 (q, 1H, J = 6.5 Hz, H-1´); 3.55 (dd, 1H, J 
= 7.9, 11.8 Hz, H-3); 2.28 (ddd, 1H, J = 5.3, 7.8, 12.9 Hz, H-4A); 1.89 („dd“, 1H, J = 11.8, 12.9 Hz, 
H-4B); 1.42 (d, 3H, J = 6.5 Hz, H-2´); 13C NMR (75 MHz, CDCl3):  = 176.4 (C-2); 144.6, 141.9, 
129.6, 128.6, 127.5, 127.1, 127.0, 113.8 (C-Ar, C-Het); 74.0 (C-5); 58.5, 57.5 (C-3, C-1´); 40.3 (C-
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4); 24.7 (C-2´); IR (ATR): 3354, 2972, 1777, 1430, 1153, 1137, 912, 807, 697, 488 cm-1. Anal. 
Calcd. For C16H16BrNO2S: C 52.47, H 4.40, N 3.82. Found: C 52.13, H 4.39, N 3.69. 
General procedure for Sonogashira coupling process  
To a stirred mixture of lactone (trans-17A-C or cis-17A-C) (1 mmol) and corresponding alkyne (3 
mmol) in Et3N (12 mL) at room temperature were added CuI (19 mg, 0.1 mmol) and 
tetrakis(triphenylphosphine)palladium (Pd(PPh3)4, 57.8 mg, 0.05 mmol). The resulting mixture 
was stirred at indicated temperature until TLC analysis had shown complete consumption of 
starting material. The reaction mixture was concentrated and mixture of hexane/EtOAc = 1:1 
(15 mL) was added. The brown solid was filtered off and washed with mixture of hexane/EtOAc 
= 1:1 (3 × 5 mL). Filtrate was concentrated under reduced pressure and the crude product was 
purified by flash column chromatography to yield the desired product trans-19A-C or cis-20A-C. 
(3R,5S)-5-(3-Dec-1-ynyl-phenyl)-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-2(3H)-one (trans-
19Aa). This product was prepared according to the general procedure; compound trans-19Aa 
(346 mg, 83%) was obtained as a pale brown oil after purification by flash column 
chromatography, eluting with hexane/EtOAc (7:1 up to 3:1). TLC: Rf = 0.27 (hexane/EtOAc 3:1, 
UV, KMnO4); []D
20 = +85 (c 0.2, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.54-7.44 (m, 1H, H-Ar); 
7.40-7.18 (m, 7H, H-Ar); 7.05 (d, 1H, J = 7.6 Hz, H-Ar); 5.48 (dd, 1H, J = 3.8, 7.9 Hz, H-5); 4.03 (q, 
1H, J = 6.6 Hz, H-1´); 3.47 (t, 1H, J = 8.2 Hz, H-3); 2.38 (t, 2H, J = 7.0 Hz, H-3´´); 2.22 (td, 1H, J = 
8.2, 13.0 Hz, H-4A); 2.03 (ddd, 1H, J = 4.0, 8.0, 12.6 Hz, H-4B); 1.64-1.55 (m, 2H, H-4´´); 1.48-1.41 
(m, 2H, H-5´´); 1.39 (d, 3H, J = 6.5 Hz, H-2´); 1.38-1.22 (m, 8H, H-6´´-H-9´´); 0.88 (t, 3H, J = 6.7 Hz, 
H-10´´); 13C NMR (75 MHz, CDCl3):  = 177.3 (C-2); 144.8, 139.5, 131.3, 128.7, 128.0, 127.4, 
126.9, 124.7, 123.9 (C-Ar); 91.4, 80.0 (C-1´´, C-2´´); 78.0 (C-5); 57.8, 54.6 (C-3, C-1´); 38.7 (C-4); 
31.9 (C-3´´); 29.2 (C-4´´); 29.2 (C-5´´); 29.0 (C-6´´); 28.7 (C-7´´); 24.7 (C-2´); 22.7 (C-8´´); 19.4 (C-
9´´); 14.1 (C-10´´); IR (ATR): 3322, 2926, 2841, 1769, 1611, 1469, 1191, 1115, 1041, 792, 700  
cm-1. HRMS (ESI): m/z [M + H]+ calcd for C28H36NO2: 418.27460; found: 418.27482. 
(3R,5S)-5-(3-Hex-1-ynyl-phenyl)-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-2(3H)-one (trans-
19Ab). This product was prepared according to the general procedure; compound trans-19Ab 
(247 mg, 69%) was obtained as pale brown oil after purification by flash column 
chromatography, eluting with hexane/EtOAc (7:1 up to 3:1). TLC: Rf = 0.27 (hexane/EtOAc 3:1, 
UV, KMnO4); []D
20 = +105 (c 0.29, CHCl3) (hexane:EtOAc = 6:1 – 2:1, Rf = 0.24); 
1H NMR (300 
MHz, CDCl3):  = 7.36-7.19 (m, 8H, H-Ar); 7.08-7.02 (m, 1H, H-Ar); 5.48 (dd, 1H, J = 3.8, 7.9 Hz, H-
5); 4.04 (q, 1H, J = 6.6 Hz, H-1´); 3.47 (t, 1H, J = 8.2 Hz, H-3); 2.40 (t, 2H, J = 7.0 Hz, H-3´´); 2.22 
(td, 1H, J = 8.1, 13.1 Hz, H-4A); 2.03 (ddd, 1H, J = 3.9, 8.1, 13.0 Hz, H-4B); 1.64-1.54 (m, 2H, H-
4´´); 1.52-1.42 (m, 2H, H-5´´); 1.39 (d, 3H, J = 6.5 Hz, H-2´); 0.94 (t, 3H, J = 6.7 Hz, H-6´´); 13C NMR 
(75 MHz, CDCl3):  = 177.3 (C-2); 144.8, 139.5, 131.3, 128.7, 128.0, 127.4, 126.9, 124.7, 123.9 (C-
Ar); 91.3, 80.0 (C-1´´, C-2´´); 78.0 (C-5); 57.8, 54.6 (C-3, C-1´); 38.7 (C-4); 30.8 (C-3´´); 24.7 (C-2´); 
22.0 (C-4´´); 19.1 (C-5´´); 13.7 (C-6´´); IR (ATR): 3315, 2929, 2831, 1771, 1600, 1454, 1189, 1160, 





2(3H)-one (trans-19Ac). This product was prepared according to the general procedure; 
compound trans-19Ac (217 mg, 60%) was obtained as pale yellow oil after purification by flash 
column chromatography, eluting with hexane/EtOAc (4:1 up to 2:1). TLC: Rf = 0.28 
(hexane/EtOAc 2:1, UV, KMnO4); []D
20 = +108 (c 0.27, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 
7.37-7.19 (m, 8H, H-Ar); 7.06-7.01 (m, 1H, H-Ar); 5.48 (dd, 1H, J = 3.8, 7.9 Hz, H-5); 4.04 (q, 1H, J 
= 6.6 Hz, H-1´); 3.47 (t, 1H, J = 8.2 Hz, H-3); 2.22 (td, 1H, J = 8.2, 13.4 Hz, H-4A); 2.03 (ddd, 1H, J = 
3.8, 8.1, 13.0 Hz, H-4B); 1.39 (d, 3H, J = 6.6 Hz, H-2´); 1.31 (s, 3H, H-4´´, 6H, 2 × CH3); 
13C NMR (75 
MHz, CDCl3):  = 177.34 (C-2); 144.8, 139.4, 131.2, 128.5, 128.5, 127.9, 127.3, 126.9, 124.6, 
123.8 (C-Ar); 99.3, 78.4 (C-1´´, C-2´´); 77.9 (C-5); 57.7, 54.6 (C-3, C-1´); 38.7 (C-4); 30.9 (C-3´´); 
27.9 (C-4´´, 2 × CH3); 24.6 (C-2´); IR (ATR): 3323, 2967, 1771, 1452, 1299, 1176, 1155, 1043, 798, 
762, 699, 541 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C24H28NO2: 362.21200; found: 362.21095.  
(3R,5S)-3-{[(1R)-1-Phenylethyl]amino}-5-(3-phenylethynyl-phenyl)dihydrofuran-2(3H)-one 
(trans-19Ad). This product was prepared according to the general procedure; compound trans-
19Ad (313 mg, 82%) was obtained as an off-white solid after purification by flash column 
chromatography, eluting with hexane/EtOAc (8:1 up to 3:1). TLC: Rf = 0.28 (hexane/EtOAc 3:1, 
UV, KMnO4); Mp =  93-94 °C (hexane/Et2O); []D
20 = +133 (c 0.63, CHCl3);
1H NMR (300 MHz, 
CDCl3):  = 7.55-7.47 (m, 2H, H-Ar); 7.46-7.42 (m, 1H, H-Ar); 7.40-7.20 (m, 10H, H-Ar); 7.15-7.09 
(m, 1H, H-Ar); 5.52 (dd, 1H, J = 3.9, 7.9 Hz, H-5); 4.05 (q, 1H, J = 6.6 Hz, H-1´); 3.49 (t, 1H, J = 8.2 
Hz, H-3); 2.25 (td, 1H, J = 8.1, 13.1 Hz, H-4A); 2.06 (ddd, 1H, J = 3,9, 7.4, 8.0 Hz, H-4B); 1.39 (d, 
3H, J = 6.6 Hz, H-2´); 13C NMR (75 MHz, CDCl3):  = 177.2 (C-2); 144.8, 139.7, 131.6, 131.3, 128.8, 
128.5, 128.4, 128.0, 127.4, 126.9, 124.7, 123.9, 122.9 (C-Ar); 90.1, 88.7 (C-1´´, C-2´´); 77.9 (C-5); 
57.8, 54.6 (C-3, C-1´); 38.7 (C-4); 24.7 (C-2´); IR (ATR): 3322, 2927, 1786, 1611, 1455, 1174, 1122, 
1054, 791, 764, 700 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C26H24NO2: 382.18016; found: 
382.18003. 
(3R,5S)-5-[(3-(4-Methoxy-phenylethynyl)-phenyl]-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-
2(3H)-one (trans-19Ae). This product was prepared according to the general procedure; 
compound trans-19Ae (296 mg, 72%) was obtained as pale yellow oil after purification by flash 
column chromatography, eluting with hexane/EtOAc (4:1 up to 2:1). TLC: Rf = 0.26 
(hexane/EtOAc 2:1, UV, KMnO4); []D
20 = +131 (c 0.19, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 
7.50-7.20 (m, 10H, H-Ar); 7.12-7.05 (m, 1H, H-Ar); 6.87 (d, 2H, J = 8.5 Hz, H-Ar); 5.51 (dd, 1H, J = 
3.8, 7.9 Hz, H-5); 4.05 (q, 1H, J = 6.6 Hz, H-1´); 3.82 (s, 3H, OCH3); 3.49 (t, 1H, J = 8.2 Hz, H-3); 
2.24 (td, 1H, J = 8.2, 13.1 Hz, H-4A); 2.06 (ddd, 1H, J = 3.9, 8.1, 13.0 Hz, H-4B); 1.40 (d, 3H, J = 6.6 
Hz, H-2´). 13C NMR (75 MHz, CDCl3):  = 177.2 (C-2); 159.8, 144.8, 139.6, 133.1, 131.1, 128.8, 
128.5, 127.8, 127.3, 126.9, 124.3. 143.2, 114.9, 114.0 (C-Ar); 90.1, 87.4 (C-1´´, C-2´´); 77.9 (C-5); 
57.8, 55.3, 54.6 (C-3, C-1´, OCH3); 38.7 (C-4); 24.7 (C-2´); IR (ATR): 3321, 2960, 2837, 2210, 1770, 
1599, 1509, 1246, 1171, 1027, 830, 762, 700, 536 cm-1.  
(3R,5S)-5-(4-Dec-1-ynyl-phenyl)-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-2(3H)-one (trans-
19Ba). This product was prepared according to the general procedure; compound trans-19Ba 
(301 mg, 72%) was obtained as an off-white solid after purification by flash column 
chromatography, eluting with hexane/EtOAc (10:1 up to 2:1). TLC: Rf = 0.32 (hexane/EtOAc 2:1, 
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UV, KMnO4); Mp =  50-51 °C (hexane/Et2O); []D
20 = +126 (c 0.3, CHCl3); 
1H NMR (300 MHz, 
CDCl3):  = 7.36-7.22 (m, 7H, H-Ar); 7.07 (d, 2H, J = 8.1 Hz, H-Ar); 5.50 (dd, 1H, J = 3.8, 8.9 Hz, H-
5); 4.04 (q, 1H, J = 6.6 Hz, H-1´); 3.45 (t, 1H, J = 8.2 Hz, H-3); 2.38 (t, 2H, J = 7.0 Hz, H-3´´); 2.27-
2.16 (m, 1H, H-4A); 2.01 (ddd, 1H, J = 3.9, 8.1, 13.0 Hz, H-4B); 1.64-1.53 (m, 2H, H-4´´); 1.48-1.41 
(m, 2H, H-5´´); 1.39 (d, 3H, J = 6.5 Hz, H-2´); 1.34-1.25 (m, 8H, H-6´´-H-9´´); 0.88 (t, 3H, J = 6.7 Hz, 
H-10´´); 13C NMR (75 MHz, CDCl3):  = 177.2 (C-2); 144.7, 138.4, 131.8, 128.5, 127.4, 126.9, 
124.8, 124.2 (C-Ar); 91.4, 79.9 (C-1´´, C-2´´); 78.1 (C-5); 57.8, 54.6 (C-3, C-1´); 38.6 (C-4); 31.8 (C-
3´´); 29.2 (C-4´´); 29.1 (C-5´´); 28.9 (C-6´´); 28.7 (C-7´´); 24.6 (C-2´); 22.7 (C-8´´); 19.4 (C-9´´); 14.1 
(C-10´´); IR (ATR): 3550, 2910, 2837, 1722, 1644, 1539, 1467, 1098, 1026, 1011, 700 cm-1. HRMS 
(ESI): m/z [M + H]+ calcd for C28H36NO2: 418.27406; found: 418.27370. 
(3R,5S)-5-(4-Hex-1-ynyl-phenyl)-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-2(3H)-one (trans-
19Bb). This product was prepared according to the general procedure; compound trans-19Bb 
(152 mg, 42%) was obtained as an off-white solid after purification by flash column 
chromatography, eluting with hexane/EtOAc (7:1 up to 2:1). TLC: Rf = 0.28 (hexane/EtOAc 2:1, 
UV, KMnO4); Mp =  64-64 °C (hexane/Et2O); []D
20 = +141 (c 0.25, CHCl3); 
1H NMR (300 MHz, 
CDCl3):  = 7.39-7.24 (m, 7H, H-Ar); 7.07 (d, 2H, J = 8.2 Hz, H-Ar); 5.50 (dd, 1H, J = 3.8, 7.9 Hz, H-
5); 4.04 (q, 1H, J = 6.6 Hz, H-1´); 3.45 (t, 1H, J = 8.2 Hz, H-3); 2.39 (t, 2H, J = 6.9 Hz, H-3´´); 2.22 
(td, 1H, J = 8.2, 13.1 Hz, H-4A); 2.01 (ddd, 1H, J = 3.9, 8.1, 12.9 Hz, H-4B); 1.66-1.54 (m, 2H, H-
4´´); 1.51-1.44 (m, 2H, H-5´´); 1.39 (d, 3H, J = 6.6 Hz, H-2´); 0.94 (t, 3H, J = 7.2 Hz, H-6´´); 13C NMR 
(75 MHz, CDCl3):  = 177.2 (C-2); 144.7, 138.4, 131.8, 128.5, 127.4, 126.9, 124.8, 124.1 (C-Ar); 
91.3, 79.9 (C-1´´, C-2´´); 78.1 (C-5); 57.8, 54.6 (C-3, C-1´); 38.7 (C-4); 30.8 (C-3´´); 24.6 (C-2´); 22.0 
(C-4´´); 19.1 (C-5´´); 13.6 (C-6´´); IR (ATR): 3332, 2922, 2855, 1769, 1620, 1455, 1188, 1115, 1046, 
792, 699 cm-1. Anal. Calcd. For C24H27NO2: C 79.74, H 7.53, N 3.87. Found: C 79.51, H 7.65, N 
3.77. 
(3R,5S)-5-[(4-(3,3-Dimethyl-but-1-ynyl)-phenyl]-3-{[(1R)-1-phenylethyl]amino}dihydro-furan-
2(3H)-one (trans-19Bc). This product was prepared according to the general procedure; 
compound trans-19Bc (184 mg, 51%) was obtained as an off-white solid after purification by 
flash column chromatography, eluting with hexane/EtOAc (10:1 up to 2:1). TLC: Rf = 0.28 
(hexane/EtOAc 2:1, UV, KMnO4); Mp =   98-100 °C (hexane/Et2O); []D
20 = +135 (c 0.17, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.38-7.20 (m, 7H, H-Ar); 7.06 (d, 2H, J = 8.1 Hz, H-Ar); 5.49 (dd, 
1H, J = 3.7, 7.9 Hz, H-5); 4.02 (q, 1H, J = 6.6 Hz, H-1´); 3.43 (t, 1H, J = 8.3 Hz, H-3); 2.20 (td, 1H, J = 
8.2, 13.0 Hz, H-4A); 1.99 (ddd, 1H, J = 3.8, 8.0, 12.9 Hz, H-4B); 1.38 (d, 3H, J = 6.6 Hz, H-2´); 1.29 
(s, 3H, H-4´´, 6H, 2 × CH3); 
13C NMR (75 MHz, CDCl3):  = 177.3 (C-2); 144.7, 138.4, 131.9, 128.5, 
127.4, 126.9, 124.7, 124.1 (C-Ar); 99.4, 78.4 (C-1´´, C-2´´); 78.1 (C-5); 57.8, 54.6 (C-3, C-1´); 38.8 
(C-4); 31.0 (C-3´´); 28.0 (C-4´´, 2 × CH3); 24.6 (C-2´); IR (ATR): 3320, 2931, 2825, 1771, 1602, 1433, 
1175, 1091, 1033, 786, 702 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C24H28NO2: 362.21200; 
found: 362.21134. 
(3R,5S)-3-{[(1R)-1-Phenylethyl]amino}-5-(4-phenylethynylphenyl)dihydrofuran-2(3H)-one 
(trans-19Bd). This product was prepared according to the general procedure; compound trans-
19Bd (271 mg, 71%) was obtained as an off-white solid after purification by flash column 
chromatography, eluting with hexane/EtOAc (10:1 up to 2:1). TLC: Rf = 0.32 (hexane/EtOAc 2:1, 
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UV, KMnO4); Mp =  118-119 °C (hexane/Et2O); []D
20 = +164 (c 0.13, CHCl3); 
1H NMR (300 MHz, 
CDCl3):  = 7.55-7.46 (m, 4H, H-Ar); 7.36-7.24 (m, 8H, H-Ar); 7.15 (d, 2H, J = 8.1 Hz, H-Ar); 5.53 
(dd, 1H, J = 3.9, 7.9 Hz, H-5); 4.05 (q, 1H, J = 6.6 Hz, H-1´); 3.47 (t, 1H, J = 8.2 Hz, H-3); 2.24 (td, 
1H, J = 8.1, 13.1 Hz, H-4A); 2.04 (ddd, 1H, J = 3.9, 8.0, 12.9 Hz, H-4B); 1.40 (d, 3H, J = 6.6 Hz, H-
2´); 13C NMR (75 MHz, CDCl3):  = 177.1 (C-2); 144.7, 139.3, 131.9, 131.6, 128.5, 128.5, 128.4, 
127.4, 127.0, 124.9, 123.3, 123.0 (C-Ar); 90.1, 88.6 (C-1´´, C-2´´); 78.1 (C-5); 57.8, 54.6 (C-3, C-1´); 
38.7 (C-4); 24.6 (C-2’); IR (ATR): 3315, 2922, 2833, 1769, 1605, 1455, 1175, 1156, 1036, 791, 698 
cm-1. Anal. Calcd. For C26H23NO2: C 81.86, H 6.08, N 3.67. Found: C 81.53, H 6.19, N 3.51. 
(3R,5S)-5-[(4-(4-Methoxy-phenylethynyl)-phenyl]-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-
2(3H)-one (trans-19Be). This product was prepared according to the general procedure; 
compound trans-19Be (354 mg, 86%) was obtained as an off-white solid after purification by 
flash column chromatography, eluting with hexane/EtOAc (8:1 up to 2:1). TLC: Rf = 0.32 
(hexane/EtOAc 2:1, UV, KMnO4); Mp =  121-122 °C (hexane/Et2O); []D
20 = +150 (c 0.2, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.50-7.42 (m, 4H, H-Ar); 7.36-7.24 (m, 5H, H-Ar); 7.13 (d, 2H, J = 
8.3 Hz, H-Ar); 6.87 (d, 2H, J = 8.5 Hz, H-Ar); 5.53 (dd, 1H, J = 3.8, 7.8 Hz, H-5); 4.05 (q, 1H, J = 6.6 
Hz, H-1´); 3.82 (s, 3H, OCH3); 3.47 (t, 1H, J = 8.2 Hz, H-3); 2.24 (td, 1H, J = 8.1, 13.1 Hz, H-4A); 
2.04 (ddd, 1H, J = 3.9, 8.0, 13.1 Hz, H-4B); 1.40 (d, 3H, J = 6.6 Hz, H-2´); 13C NMR (75 MHz, CDCl3): 
 = 177.2 (C-2); 159.8, 144.7, 138.9, 133.1, 131.8, 128.5, 127.4, 127.0, 124.9, 123.6, 123.0, 
115.1, 114.0 (C-Ar); 90.1, 87.4 (C-1´´, C-2´´); 78.1 (C-5); 57.8, 55.3, 54.6 (C-3, C-1´, OCH3); 38.7 (C-
4); 24.6 (C-2´); IR (ATR): 3319, 2923, 2828, 1772, 1602, 1454, 1178, 1145, 1029, 798, 767, 699 
cm-1. Anal. Calcd. For C26H23NO2: C 78.81, H 6.12, N 3.40. Found: C 78.56, H 6.21, N 3.32. 
(3R,5S)-5-(5-Dec-1-ynyl-thiophen-2-yl)-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-2(3H)-one 
(trans-19Ca). This product was prepared according to the general procedure; compound trans-
19Ca (305 mg, 72%) was obtained as colorless oil after purification by flash column 
chromatography, eluting with hexane/EtOAc (10:1 up to 3:1). TLC: Rf = 0.30 (hexane/EtOAc 3:1, 
UV, KMnO4); []D
20 = +128 (c 0.2, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.40-7.27 (m, 5H, H-Ar); 
6.92 (d, 1H, J = 3.7 Hz, H-Het); 6.72 (d, 1H, J = 3.7 Hz, H-Het); 5.61 (dd, 1H, J = 3.1, 7.7 Hz, H-5); 
4.05 (q, 1H, J = 6.6 Hz, H-1´); 3.59 (t, 1H, J = 8.6 Hz, H-3); 2.41 (t, 2H, J = 7.1 Hz, H-3´´); 2.25-2.15 
(m, 1H, H-4A); 2.14-2.05 (m, 1H, H-4B); 1.64-1.53 (m, 2H, H-4´´); 1.48-1.44 (m, 2H, H-5´´); 1.42 
(d, 3H, J = 6.6 Hz, H-2´); 1.34-1.24 (m, 8H, H-6´´-H-9´´); 0.89 (t, 3H, J = 6.7 Hz, H-10´´). 13C NMR 
(75 MHz, CDCl3):  = 176.5 (C-2); 144.6, 141.8, 130.7, 128.5, 127.5, 127.0, 125.2, 125.1 (C-Ar, C-
Het); 95.8, 73.1 (C-1´´, C-2´´); 74.7 (C-5); 58.2, 55.1 (C-3, C-1´); 38.5 (C-4); 31.8 (C-3´´); 29.2 (C-
4´´); 29.1 (C-5´´); 28.9 (C-6´´); 28.4 (C-7´´); 24.5 (C-2´); 22.6 (C-8´´); 19.7 (C-9´´); 14.1 (C-10´´); IR 
(ATR): 3321, 2923, 2853, 1775, 1453, 1186, 1151, 803, 762, 700, 552 cm-1. HRMS (ESI): m/z [M + 
H]+ calcd for C26H34NO2S: 424.23103; found: 424.23042. 
(3R,5S)-5-(5-Hex-1-ynyl-thiophen-2-yl)-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-2(3H)-one 
(trans-19Cb). This product was prepared according to the general procedure; compound trans-
19Cb (305 mg, 83%) was obtained as colorless oil after purification by flash column 
chromatography, eluting with hexane/EtOAc (10:1 up to 2:1). TLC: Rf = 0.31 (hexane/EtOAc 2:1, 
UV, KMnO4); []D
20 = +163 (c 0.2, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.38-7.23 (m, 5H, H-Ar); 
6.92 (d, 1H, J = 3.7 Hz, H-Het); 6.71 (d, 1H, J = 3.7 Hz, H-Het); 5.59 (dd, 1H, J = 3.1, 7.5 Hz, H-5); 
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4.04 (q, 1H, J = 6.6 Hz, H-1´); 3.58 (t, 1H, J = 8.6 Hz, H-3); 2.40 (t, 2H, J = 7.0 Hz, H-3´´); 2.24-2.15 
(m, 1H, H-4A); 2.14-2.04 (m, 1H, H-4B); 1.62-1.52 (m, 2H, H-4´´); 1.51-1.44 (m, 2H, H-5´´); 1.41 
(d, 3H, J = 6.6 Hz, H-2´); 0.93 (t, 3H, J = 7.2 Hz, H-6´´); 13C NMR (75 MHz, CDCl3):  = 176.6 (C-2); 
144.7, 141.8, 130.7, 128.6, 127.5, 127.0, 125.2, 125.1 (C-Ar, C-Het); 95.8, 73.1 (C-1´´, C-2´´); 74.7 
(C-5); 58.2, 55.1 (C-3, C-1´); 38.5 (C-4); 30.5 (C-3´´); 24.5 (C-2´); 22.0 (C-4´´); 19.4 (C-5´´); 13.6 (C-
6´´); IR (ATR): 3322, 2927, 2863, 1769, 1444, 1184, 1135, 801, 761, 700, 555 cm-1. HRMS (ESI): 
m/z [M + H]+ calcd for C22H26NO2S: 368.16842; found: 368.16764. 
(3R,5S)-5-[(5-(3,3-Dimethyl-but-1-ynyl)-thiophen-2-yl]-3-{[(1R)-1-phenylethyl]amino}dihydro-
furan-2(3H)-one (trans-19Cc). This product was prepared according to the general procedure; 
compound trans-19Cc (254 mg, 69%) was obtained as a white solid after purification by flash 
column chromatography, eluting with hexane/EtOAc (10:1 up to 2:1). TLC: Rf = 0.30 
(hexane/EtOAc 2:1, UV, KMnO4); Mp = 108-110 °C; []D
20 = +177 (c 0.2, CHCl3); 
1H NMR (300 
MHz, CDCl3):  = 7.38-7.23 (m, 5H, H-Ar); 6.90 (d, 1H, J = 3.7 Hz, H-Het); 6.70 (d, 1H, J = 3.7 Hz, H-
Het); 5.59 (dd, 1H, J = 3.1, 7.7 Hz, H-5); 4.03 (q, 1H, J = 6.6 Hz, H-1´); 3.57 (t, 1H, J = 8.6 Hz, H-3); 
2.24-2.13 (m, 1H, H-4A); 2.08 (ddd, 1H, J = 3.3, 8.1, 13.1 Hz, H-4B); 1.41 (d, 3H, J = 6.6 Hz, H-2´); 
1.28 (s, 3H, H-4´´, 6H, 2 × CH3); 
13C NMR (75 MHz, CDCl3):  = 176.6 (C-2); 144.6, 141.9, 130.7, 
128.6, 127.5, 127.0, 125.2, 125.1 (C-Ar, C-Het); 103.5, 71.7 (C-1´´, C-2´´); 74.7 (C-5); 58.2, 55.0 (C-
3, C-1´); 38.5 (C-4); 30.7 (C-3´´); 28.2 (C-4´´, 2 × CH3); 24.5 (C-2´); IR (ATR): 3321, 2923, 2853, 
1775, 1453, 1186, 1151, 803, 762, 700, 552 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C22H26NO2S: 
368.16788; found: 368.16780. 
 (3R,5S)-3-{[(1R)-1-Phenylethyl]amino}-5-(5-phenylethynyl-thiophen-2-yl)-dihydrofuran-2(3H)-
one (trans-19Cd). This product was prepared according to the general procedure; compound 
trans-19Cd (291 mg, 75%) was obtained as a white solid after purification by flash column 
chromatography, eluting with hexane/EtOAc (10:1 up to 2:1). TLC: Rf = 0.34 (hexane/EtOAc 2:1, 
UV, KMnO4); Mp = 103-104 °C; []D
20 = +216 (c 0.24, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.55-
7.44 (m, 2H, H-Ar); 7.40-7.24 (m, 8H, H-Ar); 7.07 (d, 1H, J = 3.7 Hz, H-Het); 6.78 (d, 1H, J = 3.7 Hz, 
H-Het); 5.63 (dd, 1H, J = 3.1, 7.7 Hz, H-5); 4.04 (q, 1H, J = 6.6 Hz, H-1´); 3.59 (t, 1H, J = 8.6 Hz, H-
3); 2.27-2.15 (m, 1H, H-4A); 2.14-2.04 (m, 1H, H-4B); 1.41 (d, 3H, J = 6.6 Hz, H-2´); 13C NMR (75 
MHz, CDCl3):  = 176.6 (C-2); 144.7, 143.4, 131.8, 131.5, 128.7, 128.6, 128.6, 128.4, 127.5, 127.0, 
125.3, 124.2, 122.5 (C-Ar, C-Het); 94.0, 81.9 (C-1´´, C-2´´); 74.6 (C-5); 58.2, 55.1 (C-3, C-1´); 38.6 
(C-4); 24.5 (C-2´); IR (ATR): 3321, 2926, 2844, 1775, 1453, 1177, 800, 764, 698, 553 cm-1. HRMS 
(ESI): m/z [M + H]+ calcd for C24H22NO2S: 388.13658; found: 388.13640. 
(3R,5S)-5-[(5-(4-Methoxy-phenylethynyl)-thiophen-2-yl]-3-{[(1R)-1-phenyl-ethyl]amino}-
dihydrofuran-2(3H)-one (trans-19Ce). This product was prepared according to the general 
procedure; compound trans-19Ce (284 mg, 68%) was obtained as a white solid after purification 
by flash column chromatography, eluting with hexane/EtOAc (4:1 up to 2:1). TLC: Rf = 0.33 
(hexane/EtOAc 2:1, UV, KMnO4); Mp = 98-100 °C; []D
20 = +159 (c 0.2, CHCl3); 
1H NMR (300 MHz, 
CDCl3):  = 7.45-7.25 (m, 7H, H-Ar); 7.05 (d, 1H, J = 3.7 Hz, H-Het); 6.95-6.85 (m, 2H, H-Ar); 6.76 
(dd, 1H, J = 0.9, 3.7 Hz, H-Het); 5.62 (dd, 1H, J = 3.1, 7.7 Hz, H-5); 4.04 (q, 1H, J = 6.6 Hz, H-1´); 
3.82 (s, 3H, OCH3); 3.59 (dd, 1H, J = 8.2, 8.9 Hz, H-3); 2.26-2.17 (m, 1H, H-4A); 2.15-2.04 (m, 1H, 
H-4B); 1.41 (d, 3H, J = 6.6 Hz, H-2´); 13C NMR (75 MHz, CDCl3):  = 177.6 (C-2); 160.0, 144.7, 
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142.8, 133.0, 131.2, 128.6, 127.5, 127.0, 125.3, 124.7, 114.6, 114.1 (C-Ar, C-Het); 94.1, 80.6 (C-
1´´, C-2´´); 74.6 (C-5); 58.2, 55.3, 55.1 (C-3, C-1´, OCH3); 38.6 (C-4); 24.5 (C-2´); IR (ATR): 3322, 
2921, 2845, 1768, 1455, 1187, 1122, 801, 760, 701, 555 cm-1. HRMS (ESI): m/z [M + H]+ calcd for 
C25H23NO3S: 418.14714; found: 418.14719. 
(3R,5R)-5-(3-Dec-1-ynyl-phenyl)-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-2(3H)-one (cis-
20Aa). This product was prepared according to the general procedure; compound cis-20Aa (355 
mg, 85%) was obtained as pale brown oil after purification by flash column chromatography, 
eluting with hexane/EtOAc (8:1 up to 4:1). TLC: Rf = 0.26 (hexane/EtOAc 4:1, UV, KMnO4); []D
20 
= -28 (c 0.14, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.39-7.20 (m, 8H, H-Ar); 7.17-7.12 (m, 1H, H-
Ar); 5.09 (dd, 1H, J = 5.2, 11.1 Hz, H-5); 4.14 (q, 1H, J = 6.5 Hz, H-1´); 3.59 (dd, 1H, J = 7.9, 11.9 
Hz, H-3); 2.38 (t, 2H, J = 7.0 Hz, H-3´´); 2.26 (ddd, 1H, J = 5.3, 7.9, 12.9 Hz, H-4A); 1.75 („dd“, 1H, J 
= 12.1, 12.4 Hz, H-4B); 1.64-1.54 (m, 2H, H-4´´); 1.48-1.37 (m, 2H, H-5´´); 1.41 (d, 3H, J = 6.5 Hz, 
H-2´); 1.34-1.24 (m, 8H, H-6´´-H-9´´); 0.89 (t, 3H, J = 6.6 Hz, H-10´´); 13C NMR (75 MHz, CDCl3):  = 
177.3 (C-2); 144.8, 138.4, 131.7, 128.7, 128.6, 128.5, 127.4, 127.0, 124.6 (C-Ar); 91.3, 79.9  (C-
1´´, C-2´´); 78.0 (C-5); 58.5, 57.7 (C-3, C-1´); 40.9 (C-4); 31.8 (C-3´´); 29.2 (C-4´´); 29.1 (C-5´´); 28.9 
(C-6´´); 28.7 (C-7´´); 24.8 (C-2´); 22.7 (C-8´´); 19.4 (C-9´´); 14.1 (C-10´´); IR (ATR): 3323, 2924, 
1774, 1452, 1165, 1148, 1013, 795, 763, 699, 457 cm-1. HRMS (ESI): m/z [M + H]+ calcd for 
C28H36NO2: 418.27460; found: 418.27542. 
(3R,5R)-5-(3-Hex-1-ynyl-phenyl)-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-2(3H)-one (cis-
20Ab). This product was prepared according to the general procedure; compound cis-20Ab (242 
mg, 67%) was obtained as pale brown oil after purification by flash column chromatography, 
eluting with hexane/EtOAc (7:1 up to 3:1). TLC: Rf = 0.28 (hexane/EtOAc 3:1, UV, KMnO4); []D
20 
= -18 (c 0.34, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.38-7.20 (m, 8H, H-Ar); 7.16-7.11 (m, 1H, H-
Ar); 5.09 (dd, 1H, J = 5.2, 11.1 Hz, H-5); 4.14 (q, 1H, J = 6.5 Hz, H-1´); 3.59 (dd, 1H, J = 7.9, 11.9 
Hz, H-3); 2.39 (t, 2H, J = 6.9 Hz, H-3´´); 2.26 (ddd, 1H, J = 5.3, 7.8, 12.9 Hz, H-4A); 1.75 („dd“, 1H, J 
= 12.0, 12.6 Hz, H-4B); 1.62-1.44 (m, 2H, H-4´´, 2H, H-5´´); 1.41 (d, 3H, J = 6.5 Hz, H-2´); 0.94 (t, 
3H, J = 6.6 Hz, H-6´´); 13C NMR (75 MHz, CDCl3):  = 177.3 (C-2); 144.8, 138.5, 131.7, 128.8, 
128.6, 128.5, 127.4, 127.1, 124.7, 127.7 (C-Ar); 91.3, 80.0 (C-1´´, C-2´´); 78.0 (C-5); 58.5, 57.7 (C-
3, C-1´); 40.9 (C-4); 30.8 (C-3´´); 24.8 (C-2´); 22.0 (C-4´´); 19.1 (C-5´´); 13.7 (C-6´´); IR (ATR): 3320, 
2935, 1711, 1436, 1198, 1156, 1010, 796, 700, 452 cm-1. HRMS (ESI): m/z [M + H]+ calcd for 
C24H28NO2: 362.21200; found: 362.21105. 
(3R,5R)-5-[(3-(3,3-Dimethyl-but-1-ynyl)-phenyl]-3-{[(1R)-1-phenylethyl]amino}dihydro-furan-
2(3H)-one (cis-20Ac). This product was prepared according to the general procedure; compound 
cis-20Ac (108 mg, 30%) was obtained as pale yellow oil after purification by flash column 
chromatography, eluting with hexane/EtOAc (5:1 up to 3:1). TLC: Rf = 0.29 (hexane/EtOAc 3:1, 
UV, KMnO4); []D
20 = -14.2 (c 0.22, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.38-7.20 (m, 8H, H-
Ar); 7.14-7.09 (m, 1H, H-Ar); 5.09 (dd, 1H, J = 5.2, 11.1 Hz, H-5); 4.14 (q, 1H, J = 6.5 Hz, H-1´); 
3.59 (dd, 1H, J = 7.9, 11.9 Hz, H-3); 2.26 (ddd, 1H, J = 5.3, 7.9, 12.9 Hz, H-4A); 1.75 („dd“, 1H, J = 
11.9, 12.4 Hz, H-4B); 1.41 (d, 3H, J = 6.5 Hz, H-2´); 1.30 (s, 3H, H-4´´, 6H, 2 × CH3); 
13C NMR (75 
MHz, CDCl3):  = 177.4 (C-2); 144.8, 138.4, 131.6, 128.7, 128.5, 128.5, 127.4, 127.0, 124.6 (C-Ar); 
99.3, 78.4   (C-1´´, C-2´´); 78.1 (C-5); 58.5, 57.7 (C-3, C-1´); 41.0 (C-4); 31.0 (C-3´´); 27.9 (C-4´´, 2 × 
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CH3); 24.8 (C-2´); IR (ATR): 3325, 2932, 1773, 1569, 1500, 1233, 1173, 1022, 811, 697, 525 cm
-1. 
HRMS (ESI): m/z [M + H]+ calcd for C24H28NO2: 362.21200; found: 362.21113. 
(3R,5R)-3-{[(1R)-1-Phenylethyl]amino}-5-(3-phenylethynyl-phenyl)dihydrofuran-2(3H)-one 
(cis-20Ad). This product was prepared according to the general procedure; compound cis-20Ad 
(326 mg, 85%) was obtained as pale yellow oil after purification by flash column 
chromatography, eluting with hexane/EtOAc (8:1 up to 4:1). TLC: Rf = 0.29 (hexane/EtOAc 4:1, 
UV, KMnO4); []D
20 = -23.4 (c 0.4, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.55-7.17 (m, 14H, H-
Ar); 5.13 (dd, 1H, J = 5.3, 11.1 Hz, H-5); 4.15 (q, 1H, J = 6.5 Hz, H-1´); 3.61 (dd, 1H, J =7.9, 11.9 Hz, 
H-3); 2.30 (ddd, 1H, J = 5.3, 7.9, 12.9 Hz, H-4A); 1.78 („dd“, 1H, J = 11.7, 12.3 Hz, H-4B); 1.41 (d, 
3H, J = 6.5 Hz, H-2´); 13C NMR (75 MHz, CDCl3):  = 177.3 (C-2); 144.8, 138.7, 131.7, 131.6, 128.8, 
128.6, 128.5, 128.4, 127.5, 127.1, 123.9, 122.9 (C-Ar); 90.0, 88.7 (C-1´´, C-2´´); 77.9 (C-5); 58.5, 
57.7 (C-3, C-1´); 40.9 (C-4); 24.8 (C-2´); IR (ATR): 3343, 2935, 1777, 1448, 1136, 1112, 1025, 796, 
745, 702, 469 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C26H24NO2: 382.18070; found: 382.18007. 
(3R,5R)-5-[(3-(4-Methoxy-phenylethynyl)-phenyl]-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-
2(3H)-one (cis-20Ae). This product was prepared according to the general procedure; 
compound cis-20Ae (325 mg, 79%) was obtained as pale brown oil after purification by flash 
column chromatography, eluting with hexane/EtOAc (5:1 up to 3:1). TLC: Rf = 0.28 
(hexane/EtOAc 3:1, UV, KMnO4); []D
20 = -7.5 (c 0.19, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 
7.48-7.20 (m, 10H, H-Ar); 7.20-7.16 (m, 1H, H-Ar); 6.88 (d, 2H, J = 8.5 Hz, H-Ar); 5.13 (dd, 1H, J = 
5.3, 11.6 Hz, H-5); 4.15 (q, 1H, J = 6.5 Hz, H-1´); 3.83 (s, 3H, OCH3); 3.60 (dd, 1H, J = 7.9, 11.9 Hz, 
H-3); 2.29 (ddd, 1H, J = 5.3, 7.9, 13.0 Hz, H-4A); 1.78 („dd“, 1H, J = 11.8, 12.4 Hz, H-4B); 1.42 (d, 
3H, J = 6.5 Hz, H-2´); 13C NMR (75 MHz, CDCl3):  = 177.3 (C-2); 159.7, 144.8, 138.6, 133.1, 131.5, 
128.7, 128.6, 128.5, 127.4, 127.0, 125.0, 124.1, 115.0, 114.0 (C-Ar); 90.1, 87.4 (C-1´´, C-2´´); 78.0 
(C-5); 58.5, 57.7, 55.3 (C-3, C-1´, OCH3); 40.9 (C-4); 24.8 (C-2´); IR (ATR): 3325, 2929, 1770, 1599, 
1509, 1246, 1171, 1149, 1026, 830, 695, 536 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C27H26NO3: 
412.19072; found: 412.19075. 
(3R,5R)-5-(4-Dec-1-ynyl-phenyl)-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-2(3H)-one (cis-
20Ba). This product was prepared according to the general procedure; compound cis-20Ba (359 
mg, 86%) was obtained as colorless oil after purification by flash column chromatography, 
eluting with hexane/EtOAc (10:1 up to 2:1). TLC: Rf = 0.34 (hexane/EtOAc 2:1, UV, KMnO4); 
[]D
20 = -45 (c 0.18, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.39-7.20 (m, 7H, H-Ar); 7.15 (d, 2H, J 
= 8.2 Hz, H-Ar); 5.10 (dd, 1H, J = 5.2, 11.1 Hz, H-5); 4.14 (q, 1H, J = 6.5 Hz, H-1´); 3.58 (dd, 1H, J = 
7.9, 11.9 Hz, H-3); 2.38 (t, 2H, J = 7.0 Hz, H-3´´); 2.26 (ddd, 1H, J = 5.3, 7.8, 12.9 Hz, H-4A); 1.74 
(„dd“, 1H, J = 12.0, 12.3 Hz, H-4B); 1.64-1.53 (m, 2H, H-4´´); 1.48-1.37 (m, 2H, H-5´´); 1.41 (d, 3H, 
J = 6.5 Hz, H-2´); 1.36-1.22 (m, 8H, H-6´´-H-9´´); 0.88 (t, 3H, J = 6.6 Hz, H-10´´); 13C NMR (75 MHz, 
CDCl3):  = 177.3 (C-2); 144.8, 137.4, 131.8, 128.5, 127.4, 127.0, 125.5, 124.6 (C-Ar); 91.4, 80.0 
(C-1´´, C-2´´); 78.1 (C-5); 58.5, 57.7 (C-3, C-1´); 40.8 (C-4); 31.8 (C-3´´); 29.2 (C-4´´); 29.1 (C-5´´); 
28.9 (C-6´´); 28.7 (C-7´´); 24.8 (C-2´); 22.7 (C-8´´); 19.4 (C-9´´); 14.1 (C-10´´); IR (ATR): 3322, 2922, 
1759, 1445, 1126, 1102, 1025, 794, 755, 699, 456 cm-1. HRMS (ESI): m/z [M + H]+ calcd for 




20Bb). This product was prepared according to the general procedure; compound cis-20Bb (253 
mg, 70%) was obtained as an off-white solid after purification by flash column chromatography, 
eluting with hexane/EtOAc (7:1 up to 3:1). TLC: Rf = 0.30 (hexane/EtOAc 3:1, UV, KMnO4); Mp =  
63-64 °C (hexane/Et2O); []D
20 = -33 (c 0.24, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.39-7.22 (m, 
7H, H-Ar); 7.16 (d, 2H, J = 8.2 Hz, H-Ar); 5.11 (dd, 1H, J = 5.2, 11.1 Hz, H-5); 4.15 (q, 1H, J = 6.5 Hz, 
H-1´); 3.59 (dd, 1H, J = 7.9, 11.9 Hz, H-3); 2.40 (t, 2H, J = 7.0 Hz, H-3´´); 2.26 (ddd, 1H, J = 5.3, 7.8, 
12.9 Hz, H-4A); 1.75 („dd“, 1H, J = 12.0, 12.3 Hz, H-4B); 1.64-1.52 (m, 2H, H-4´´); 1.51-1.43 (m, 
2H, H-5´´); 1.41 (d, 3H, J = 6.5 Hz, H-2´); 0.95 (t, 3H, J = 7.2 Hz, H-6´´); 13C NMR (75 MHz, CDCl3):  
= 177.2 (C-2); 144.7, 137.4, 131.8, 128.5, 127.5, 127.1, 125.5, 124.6 (C-Ar); 91.3, 80.0 (C-1´´, C-
2´´); 78.1 (C-5); 58.5, 57.6 (C-3, C-1´); 40.8 (C-4); 30.8 (C-3´´); 24.7 (C-2´); 22.0 (C-4´´); 19.1 (C-5´´); 
13.6 (C-6´´); IR (ATR): 3332, 2956, 1769, 1445, 1258, 1165, 1015, 794, 763, 701, 452 cm-1. HRMS 
(ESI): m/z [M + H]+ calcd for C24H28NO2: 362,21146; found: 362,21147. 
 (3R,5R)-5-[(4-(3,3-Dimethyl-but-1-ynyl)-phenyl]-3-{[(1R)-1-phenylethyl]amino}dihydro-furan-
2(3H)-one (cis-20Bc). This product was prepared according to the general procedure; compound 
cis-20Bc (112 mg, 31%) was obtained as an off-white solid after purification by flash column 
chromatography, eluting with hexane/EtOAc (10:1 up to 2:1). TLC: Rf = 0.30 (hexane/EtOAc 2:1, 
UV, KMnO4); Mp =  103-105 °C (hexane/Et2O); []D
20 = -27.1 (c 0.25, MeOH); 1H NMR (300 MHz, 
CDCl3):  = 7.48-7.22 (m, 7H, H-Ar); 7.14 (d, 2H, J = 8.2 Hz, H-Ar); 5.10 (dd, 1H, J = 5.3, 11.0 Hz, H-
5); 4.14 (q, 1H, J = 6.5 Hz, H-1´); 3.58 (dd, 1H, J = 7.9, 12.1 Hz, H-3); 2.25 (ddd, 1H, J = 5.1, 7.8, 
12.8 Hz, H-4A); 1.73 (td, 1H, J = 11.3, 12.4 Hz, H-4B); 1.41 (d, 3H, J = 6.5 Hz, H-2´); 1.30 (s, 3H, H-
4´´, 6H, 2 × CH3); 
13C NMR (75 MHz, CDCl3):  = 177.3 (C-2); 144.8, 137.3, 131.8, 128.5, 127.4, 
127.0, 125.4, 124.5 (C-Ar); 99.4, 78.4 (C-1´´, C-2´´); 78.1 (C-5); 58.5, 57.6 (C-3, C-1´); 40.8 (C-4); 
31.0 (C-3´´); 27.9 (C-4´´, 2 × CH3); 24.8 (C-2´); IR (ATR): 3321, 2931, 1712, 1434, 1189, 1145, 
1020, 789, 699, 451 cm-1. Anal. Calcd. For C24H27NO2: C 79.74, H 7.53, N 3.87. Found: C 79.45, H 
7.59, N 3.77. 
(3R,5R)-3-{[(1R)-1-Phenylethyl]amino}-5-(4-phenylethynyl-phenyl)dihydrofuran-2(3H)-one 
(cis-20Bd). This product was prepared according to the general procedure; compound cis-20Bd 
(267 mg, 70%) was obtained as an off-white solid after purification by flash column 
chromatography, eluting with hexane/EtOAc (10:1 up to 3:1). TLC: Rf = 0.28 (hexane/EtOAc 3:1, 
UV, KMnO4); Mp =  119-121 °C (hexane/Et2O); []D
20 = -37 (c 0.49, CHCl3); 
1H NMR (300 MHz, 
CDCl3):  = 7.55-7.47 (m, 4H, H-Ar); 7.40-7.20 (m, 10H, H-Ar); 5.14 (dd, 1H, J = 5.3, 11.1 Hz, H-5); 
4.15 (q, 1H, J = 6.5 Hz, H-1´); 3.61 (dd, 1H, J = 7.9, 11.9 Hz, H-3); 2.29 (ddd, 1H, J = 5.3, 7.8, 12.9 
Hz, H-4A); 1.75 („dd“, 1H, J = 11.6, 12.1 Hz, H-4B); 1.42 (d, 3H, J = 6.5 Hz, H-2´); 13C NMR (75 
MHz, CDCl3):  = 177.3 (C-2); 144.8, 138.3, 131.9, 131.6, 128.6, 128.5, 128.4, 127.5, 127.1, 125.7, 
123.7, 123.0 (C-Ar); 90.1, 88.7 (C-1´´, C-2´´); 78.1 (C-5); 58.5, 57.7 (C-3, C-1´); 40.9 (C-4); 24.8 (C-
2´); IR (ATR): 3320, 2935, 1711, 1433, 1198, 1156, 1015, 796, 701, 452 cm-1. Anal. Calcd. For 
C26H23NO2: C 81.86, H 6.08, N 3.67. Found: C 81.58, H 6.19, N 3.72. 
(3R,5R)-5-[(4-(4-Methoxy-phenylethynyl)-phenyl]-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-
2(3H)-one (cis-20Be). This product was prepared according to the general procedure; 
compound cis-20Be (342 mg, 83%) was obtained as an off-white solid after purification by flash 
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column chromatography, eluting with hexane/EtOAc (10:1 up to 2:1). TLC: Rf = 0.34 
(hexane/EtOAc 2:1, UV, KMnO4); Mp =  97-98 °C (hexane/Et2O); []D
20 = -86 (c 0.21, CHCl3); 
1H 
NMR (300 MHz, CDCl3):  = 7.50-7.45 (m, 4H, H-Ar); 7.40-7.22 (m, 7H, H-Ar); 6.92-6.87 (m, 2H, H-
Ar); 5.15 (dd, 1H, J = 5.2, 11.1 Hz, H-5); 4.17 (q, 1H, J = 6.6 Hz, H-1´); 3.83 (s, 3H, OCH3); 3.61 (dd, 
1H, J = 7.9, 11.9 Hz, H-3); 2.30 (ddd, 1H, J = 5.2, 7.9, 12.8 Hz, H-4A); 1.79 („dd“, 1H, J = 12.0, 12.4 
Hz, H-4B); 1.48 (d, 3H, J = 6.6 Hz, H-2´); 13C NMR (75 MHz, CDCl3):  = 177.2 (C-2); 159.8, 144.8, 
137.9, 133.1, 131.7, 128.6, 127.5, 127.1, 125.7, 124.1, 115.1, 114.1 (C-Ar); 90.2, 87.5 (C-1´´, C-
2´´); 78.1 (C-5); 58.5, 57.7 (C-3, C-1´); 55.3 (OCH3); 31.9 (C-4); 24.8 (C-2´); IR (ATR): 3326, 2922, 
1725, 1445, 1189, 1155, 1016, 794, 701, 455 cm-1. Anal. Calcd. For C26H23NO2: C 78.81, H 6.12, N 
3.40. Found: C 79.13, H 6.19, N 3.51. 
(3R,5R)-5-(5-Dec-1-ynyl-thiophen-2-yl)-3-{[(1R)-1-phenylethyl]amino}dihydrofuran-2(3H)-one 
(cis-20Ca). This product was prepared according to the general procedure; compound cis-20Ca 
(326 mg, 77%) was obtained as colorless oil after purification by flash column chromatography, 
eluting with hexane/EtOAc (10:1 up to 2:1). TLC: Rf = 0.36 (hexane/EtOAc 2:1, UV, KMnO4); 
[]D
20 = -142 (c 0.39, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.39-7.24 (m, 5H, H-Ar); 6.95 (d, 1H, J 
= 3.7 Hz, H-Het); 6.84 (d, 1H, J = 3.7 Hz, H-Het); 5.27 (dd, 1H, J = 5.1, 10.9 Hz, H-5); 4.15 (q, 1H, J 
= 6.4 Hz, H-1´); 3.56 (dd, 1H, J = 7.8, 11.6 Hz, H-3); 2.40 (t, 2H, J = 7.1 Hz, H-3´´); 2.29 (ddd, 1H, J = 
5.5, 7.6, 12.8 Hz, H-4A); 1.93 („dd“, 1H, J = 11.9, 12.5 Hz, H-4B); 1.64-1.53 (m, 2H, H-4´´); 1.48-
1.38 (m, 2H, H-5´´); 1.41 (d, 3H, J = 6.4 Hz, H-2´); 1.36-1.25 (m, 8H, H-6´´-H-9´´); 0.89 (t, 3H, J = 
6.7 Hz, H-10´´); 13C NMR (75 MHz, CDCl3):  = 177.6 (C-2); 140.3, 130.6, 128.6, 127.5, 127.1, 
126.2 125.8 (C-Ar, C-Het); 95.9, 73.2 (C-1´´, C-2´´); 74.2 (C-5); 58.7, 57.5 (C-3, C-1´); 40.5 (C-4); 
31.8 (C-3´´); 29.2 (C-4´´); 29.1 (C-5´´); 28.9 (C-6´´); 28.4 (C-7´´); 24.7 (C-2´); 22.7 (C-8´´); 19.7 (C-
9´´); 14.1 (C-10´´); IR (ATR): 3314, 2923, 2822, 1759, 1601, 1455, 1175, 1022, 791, 699 cm-1. 
HRMS (ESI): m/z [M + H]+ calcd for C26H34NO2S: 424.23103; found: 424.23041. 
(3R,5R)-5-(5-Hex-1-ynyl-thiophen-2-yl)-3-{[(1R)-1-phenylethyl]amino}dihydro-furan-2(3H)-one 
(cis-20Cb). This product was prepared according to the general procedure; compound cis-20Cb 
(228 mg, 62%) was obtained as a white solid after purification by flash column chromatography, 
eluting with hexane/EtOAc (10:1 up to 3:1). TLC: Rf = 0.33 (hexane/EtOAc 3:1, UV, KMnO4); Mp = 
56-57 °C; []D
20 = -134 (c 0.2, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.39-7.25 (m, 5H, H-Ar); 6.95 
(d, 1H, J = 3.7 Hz, H-Het); 6.83 (d, 1H, J = 3.7 Hz, H-Het); 5.27 (dd, 1H, J = 5.2, 11.1 Hz, H-5); 4.15 
(q, 1H, J = 6.5 Hz, H-1´); 3.56 (dd, 1H, J = 7.9, 11.9 Hz, H-3); 2.42 (t, 2H, J = 7.0 Hz, H-3´´); 2.30 
(ddd, 1H, J = 5.3, 7.8, 12.9 Hz, H-4A); 1.93 („dd“, 1H, J = 12.0, 12.4 Hz, H-4B); 1.64-1.53 (m, 2H, 
H-4´´); 1.52-1.45 (m, 2H, H-5´´); 1.43 (d, 3H, J = 6.5 Hz, H-2´); 0.94 (t, 3H, J = 7.2 Hz, H-6´´); 13C 
NMR (75 MHz, CDCl3):  = 176.6 (C-2); 144.7, 140.3, 130.6, 128.6, 127.5, 127.1, 126.2, 125.8 (C-
Ar, C-Het); 95.8, 73.3 (C-1´´, C-2´´); 74.2 (C-5); 58.5, 57.6 (C-3, C-1´); 40.5 (C-4); 30.5 (C-3´´); 24.8 
(C-2´); 22.0 (C-4´´); 19.4 (C-5´´); 13.6 (C-6´´); IR (ATR): 3323, 2920, 1721, 1436, 1179, 1132, 1010, 
795, 698, 459 cm-1. Anal. Calcd. For C22H25NO2S: C 71.90, H 6.86, N 3.81. HRMS (ESI): m/z [M + 
H]+ calcd for C22H26NO2S: 368.16788; found: 368.16765. 
 (3R,5R)-5-[(5-(3,3-Dimethyl-but-1-ynyl)-thiophen-2-yl]-3-{[(1R)-1-phenylethyl]amino}dihydro-
furan-2(3H)-one (cis-20Cc). This product was prepared according to the general procedure; 
compound cis-20Cc (202 mg, 55%) was obtained as a white solid after purification by flash 
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column chromatography, eluting with hexane/EtOAc (10:1 up to 3:1). TLC: Rf = 0.32 
(hexane/EtOAc 3:1, UV, KMnO4); Mp = 102-103 °C; []D
20 = -130 (c 0.13, CHCl3); 
1H NMR (300 
MHz, CDCl3):  = 7.42-7.28 (m, 5H, H-Ar); 6.98 (d, 1H, J = 3.7 Hz, H-Het); 6.88 (d, 1H, J = 3.7 Hz, H-
Het); 5.31 (dd, 1H, J = 5.2, 11.1 Hz, H-5); 4.19 (q, 1H, J = 6.5 Hz, H-1´); 3.60 (dd, 1H, J = 7.9, 11.8 
Hz, H-3); 2.33 (ddd, 1H, J = 5.2, 7.8, 12.9 Hz, H-4A); 1.97 („dd“, 1H, J = 11.8, 12.3 Hz, H-4B); 1.47 
(d, 3H, J = 6.5 Hz, H-2´); 1.36 (s, 3H, H-4´´, 6H, 2 × CH3); 
13C NMR (75 MHz, CDCl3):  = 177.6 (C-2); 
144.7, 140.3, 130.5, 128.6, 127.5, 127.1, 126.2, 125.8 (C-Ar, C-Het); 103.5, 71.8 (C-1´´, C-2´´); 
74.2 (C-5); 58.5, 57.6 (C-3, C-1´); 40.5 (C-4); 30.8 (C-3´´); 28.3 (C-4´´, 2 × CH3); 24.8 (C-2´); IR 
(ATR): 3316, 2921, 2822, 1769, 1611, 1433, 1175, 1149, 1036, 785, 699 cm-1. Anal. Calcd. For 
C22H25NO2S: C 71.90, H 6.86, N 3.81. Found: C 72.21, H 6.94, N 3.72. 
(3R,5R)-3-{[(1R)-1-Phenylethyl]amino}-5-(5-phenylethynyl-thiophen-2-yl)-dihydrofuran-2(3H)-
one (cis-20Cd). This product was prepared according to the general procedure; compound cis-
20Cd (263 mg, 68%) was obtained as a white solid after purification by flash column 
chromatography, eluting with hexane/EtOAc (10:1 up to 3:1). TLC: Rf = 0.35 (hexane/EtOAc 3:1, 
UV, KMnO4); Mp = 99-101 °C; []D
20 = -161 (c 0.15, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.55-
7.48 (m, 2H, H-Ar); 7.40-7.26 (m, 8H, H-Ar); 7.13 (d, 1H, J = 3.7 Hz, H-Het); 6.92 (d, 1H, J = 3.7 Hz, 
H-Het); 5.31 (dd, 1H, J = 5.2, 11.0 Hz, H-5); 4.17 (q, 1H, J = 6.5 Hz, H-1´); 3.58 (dd, 1H, J = 7.9, 
11.8 Hz, H-3); 2.34 (ddd, 1H, J = 5.3, 7.7, 12.9 Hz, H-4A); 1.75 („dd“, 1H, J = 11.9, 12.4Hz, H-4B); 
1.44 (d, 3H, J = 6.5 Hz, H-2´); 13C NMR (75 MHz, CDCl3):  = 176.4 (C-2); 144.6, 141.8, 131.6, 
131.4, 128.7, 128.6, 128.4, 127.5, 127.1, 126.3, 124.7, 122.5 (C-Ar, C-Het); 94.0, 82.0 (C-1´´, C-
2´´); 74.1 (C-5); 58.5, 57.5 (C-3, C-1´); 40.5 (C-4); 24.7 (C-2´); IR (ATR): 3321, 2931, 1710, 1434, 
1152, 1133, 1020, 788, 699, 469 cm-1. Anal. Calcd. For C24H21NO2S: C 74.39, H 5.46, N 3.61. 
Found: C 74.79, H 5.55, N 3.55. 
(3R,5R)-5-[(5-(4-Methoxy-phenylethynyl)-thiophen-2-yl]-3-{[(1R)-1-phenylethyl]amino}-
dihydrofuran-2(3H)-one (cis-20Ce). This product was prepared according to the general 
procedure; compound cis-20Ce (234 mg, 56%) was obtained as colorless oil after purification by 
flash column chromatography, eluting with hexane/EtOAc (7:1 up to 2:1). TLC: Rf = 0.34 
(hexane/EtOAc 2:1, UV, KMnO4); []D
20 = -135 (c 0.8, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.45-
7.24 (m, 7H, H-Ar); 7.07 (d, 1H, J = 3.7 Hz, H-Het); 6.92 (d, 1H, J = 3.7 Hz, H-Het); 6.90-6.84 (m, 
2H, H-Ar); 5.29 (dd, 1H, J = 5.2, 11.0 Hz, H-5); 4.14 (q, 1H, J = 6.5 Hz, H-1´); 3.82 (s, 3H, OCH3); 
3.57 (dd, 1H, J = 7.9, 11.9 Hz, H-3); 2.31 (ddd, 1H, J = 5.3, 7.8, 12.9 Hz, H-4A); 1.94 (dd, 1H, J = 
11.8, 12.4 Hz, H-4B); 1.42 (d, 3H, J = 6.5 Hz, H-2´); 13C NMR (75 MHz, CDCl3):  = 176.6 (C-2); 
160.0, 144.7, 141.3, 133.0, 131.1, 128.6, 127.5, 127.1, 126.4, 125.2, 114.6, 114.1, 114.1 (C-Ar, C-
Het); 94.1, 80.8 (C-1´´, C-2´´); 74.1 (C-5); 58.5, 57.6 (C-3, C-1´); 55.3 (OCH3); 40.5 (C-4); 24.8 (C-
2´); IR (ATR): 3322, 2932, 2829, 1760, 1600, 1441, 1259, 1132, 1036, 801, 702 cm-1. HRMS (ESI): 
m/z [M + H]+ calcd for C25H24NO3S: 418.14714; found: 418.14718. 
General procedure for reduction of lactones to aminodiols  
Sodium borohydride (0.37 g, 10 mmol) was added to the suspension of the corresponding 
lactone (tans-19A-C or cis-20A-C) (1 mmol) in 96 % ethanol (15 mL) in one portion at room 
temperature. The reaction mixture was stirred for the indicated time at room temperature. 
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Then 5% potassium carbonate solution (20 mL) was added and the ethanol was evaporated 
under reduced pressure. The water phase was extracted with Et2O (3 X 100 mL). Organic extracts 
were dried with Na2SO4 and concentrated under vacuum. The crude product was purified by 
flash column chromatography to yield the desired diaminoalcohol anti-21A-C or syn-22A-C. 
(1R,3R)-1-(3-Dec-1-ynyl-phenyl)-3-((R)-1-phenylethylamino)-butane-1,4-diol (anti-21Aa). This 
product was prepared according to the general procedure; compound anti-21Aa (282 mg, 67%) 
was obtained as a pale yellow oil after purification by flash column chromatography, eluting 
with CH2Cl2/acetone (7:1 up to 5:1). TLC: Rf = 0.29 (CH2Cl2/acetone 5:1, UV, KMnO4); []D
20 = 
+97 (c 0.14, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.39-7.15 (m, 7H, H-Ar); 7.08 (t, 1H, J = 7.6 Hz, 
H-Ar); 6.97-6.92 (m, 1H, H-Ar); 4.85 (dd, 1H, J = 4.1, 6.2 Hz, H-1); 3.89 (q, 1H, J = 6.6 Hz, H-1´); 
3.76 (dd, 1H, J = 4.1, 10.9 Hz, H-4A); 3.40 (dd, 1H, J = 4.0, 10.9 Hz, H-4B); 2.64 (td, 1H, J = 3.8, 
12.3 Hz, H-3); 2.39 (t, 2H, J = 7.0 Hz, H-3´´); 1.92 (ddd, 1H, J = 4.0, 8.6, 14.3 Hz, H-2A); 1.70-1.54 
(m, 1H, H-2B, 2H, H-4´´); 1.48-1.42 (m, 2H, H-5´´); 1.38 (d, 3H, J = 6.6 Hz, H-2´); 1.35-1.22 (m, 8H, 
H-6´´-H-9´´); 0.88 (t, 3H, J = 6.6 Hz, H-10´´); 13C NMR (75 MHz, CDCl3):  = 144.9, 144.2, 129.9, 
128.7, 128.6, 128.0, 127.4, 127.0, 124.8, 123.7 (C-Ar); 90.2, 80.7 (C-1´´, C-2´´); 71.9 (C-1); 62.8 (C-
4); 55.1, 53.1 (C-3, C-1´); 39.5 (C-2); 31.8 (C-3´´); 29.2 (C-4´´); 29.1 (C-5´´); 29.0 (C-6´´); 28.8 (C-
7´´); 24.3 (C-2´); 22.6 (C-8´´); 19.4 (C-9´´); 14.1 (C-10´´); IR (ATR): 3286, 2920, 2857, 1435, 1139, 
1066, 1052, 795, 761, 698, 555 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C28H40NO2: 422.30536; 
found: 422.30508. 
(1R,3R)-1-(3-Hex-1-ynyl-phenyl)-3-((R)-1-phenylethylamino)-butane-1,4-diol (anti-21Ab). This 
product was prepared according to the general procedure; compound anti-21Ab (212 mg, 58%) 
was obtained as a pale yellow oil after purification by flash column chromatography, eluting 
with CH2Cl2/acetone (10:1 up to 6:1). TLC: Rf = 0.28 (CH2Cl2/acetone 6:1, UV, KMnO4); []D
20 = 
+63 (c 0.16, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.39-7.17 (m, 7H, H-Ar); 7.09 (t, 1H, J = 7.6 Hz, 
H-Ar); 6.99-6.94 (m, 1H, H-Ar); 4.88 (dd, 1H, J = 4.2, 6.1 Hz, H-1); 3.91 (q, 1H, J = 6.5 Hz, H-1´); 
3.78 (dd, 1H, J = 4.1, 10.9 Hz, H-4A); 3.43 (dd, 1H, J = 4.0, 10.9 Hz, H-4B); 2.67 (td, 1H, J = 3.8, 
12.1 Hz, H-3); 2.43 (t, 2H, J = 7.0 Hz, H-3´´); 1.95 (ddd, 1H, J = 4.0, 8.5, 14.3 Hz, H-2A); 1.73-1.65 
(m, 1H, H-2B); 1.65-1.65 (m 2H, H-4´´); 1.55-1.45 (m, 2H, H-5´´); 1.41 (d, 3H, J = 6.6 Hz, H-2´); 
0.97 (t, 3H, J = 6.6 Hz, H-6´´); 13C NMR (75 MHz, CDCl3):  = 144.9, 144.3, 130.0, 128.8, 128.7, 
128.7, 128.0, 127.4, 127.1, 124.8, 123.8 (C-Ar); 90.2, 80.7 (C-1´´, C-2´´); 71.9 (C-1); 62.9 (C-4); 
55.2, 53.1 (C-3, C-1´); 39.5 (C-2); 30.9 (C-3´´); 24.3 (C-2´); 22.1 (C-4´´); 19.1 (C-5´´); 13.7 (C-6´´); IR 
(ATR): 3276, 2922, 2850, 1451, 1122, 1080, 1059, 795, 763, 701, 544 cm-1. HRMS (ESI): m/z [M + 
H]+ calcd for C24H32NO2: 366.24276; found: 366.24258. 
(1R,3R)-1-(4-Dec-1-ynyl-phenyl)-3-((R)-1-phenylethylamino)-butane-1,4-diol (anti-21Ba). This 
product was prepared according to the general procedure; compound anti-21Ba (308 mg, 73%) 
was obtained as a pale yellow oil after purification by flash column chromatography, eluting 
with EtOAc/NH3 (100:1). TLC: Rf = 0.33 (EtOAc/NH3 100:1, UV, KMnO4); []D
20 = +50 (c 0.27, 
CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.39-7.27 (m, 5H, H-Ar); 7.20 (d, 2H, J = 8.2 Hz, H-Ar); 6.95 
(d, 2H, J = 8.2 Hz, H-Ar); 4.90 (dd, 1H, J = 4.2, 5.8 Hz, H-1); 3.89 (q, 1H, J = 6.6 Hz, H-1´); 3.78 (dd, 
1H, J = 4.1, 10.9 Hz, H-4A); 3.41 (dd, 1H, J = 3.8, 10.9 Hz, H-4B); 2.65 (td, 1H, J = 3.8, 12.4 Hz, H-
3); 2.39 (t, 2H, J = 7.0 Hz, H-3´´); 1.96 (ddd, 1H, J = 4.1, 8.9, 14.3 Hz, H-2A); 1.68-1.54 (m, 1H, H-
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2B, 2H, H-4´´); 1.48-1.37 (m, 2H, H-5´´); 1.42 (d, 3H, J = 6.6 Hz, H-2´); 1.40-1.20 (m, 8H, H-6´´-H-
9´´); 0.90 (t, 3H, J = 6.6 Hz, H-10´´); 13C NMR (75 MHz, CDCl3):  = 144.2, 131.3, 128.7, 127.5, 
127.2, 125.4, 122.3 (C-Ar); 90.0, 80.5 (C-1´´, C-2´´); 72.1 (C-1); 62.8 (C-4); 55.1, 53.0 (C-3, C-1´); 
39.4 (C-2); 31.9 (C-3´´); 29.2 (C-4´´); 29.1 (C-5´´); 29.0 (C-6´´); 28.8 (C-7´´); 24.1 (C-2´); 22.7 (C-8´´); 
19.4 (C-9´´); 14.1 (C-10´´); IR (ATR): 3288, 2923, 2854, 1453, 1059, 838, 760, 700, 553 cm-1. 
HRMS (ESI): m/z [M + H]+ calcd for C28H40NO2: 422.30536; found: 422.30523. 
(1R,3R)-1-(4-Hex-1-ynyl-phenyl)-3-((R)-1-phenylethylamino)-butane-1,4-diol (anti-21Bb). This 
product was prepared according to the general procedure; compound anti-21Bb (285 mg, 78%) 
was obtained as a pale yellow oil after purification by flash column chromatography, eluting 
with EtOAc/NH3 (100:1). TLC: Rf = 0.32 (EtOAc/NH3 100:1, UV, KMnO4); []D
20 = +62 (c 0.32, 
CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.37-7.24 (m, 5H, H-Ar); 7.19 (d, 2H, J = 8.2 Hz, H-Ar); 6.92 
(d, 2H, J = 8.2 Hz, H-Ar); 4.87 (dd, 1H, J = 3.8, 5.6 Hz, H-1); 3.87 (q, 1H, J = 6.6 Hz, H-1´); 3.76 (dd, 
1H, J = 3.9, 10.8 Hz, H-4A); 3.39 (dd, 1H, J = 3.6, 10.8 Hz, H-4B); 2.63 (td, 1H, J = 3.7, 12.4 Hz, H-
3); 2.38 (t, 2H, J = 7.0 Hz, H-3´´); 1.94 (ddd, 1H, J = 4.1, 8.8, 14.0 Hz, H-2A); 1.64-1.52 (m, 1H, H-
2B, 2H, H-4´´); 1.50-1.42 (m, 2H, H-5´´); 1.40 (d, 3H, J = 6.6 Hz, H-2´); 0.94 (t, 3H, J = 6.6 Hz, H-
6´´); 13C NMR (75 MHz, CDCl3):  = 144.2, 144.1, 131.3, 128.7, 127.5, 127.2, 125.4, 122.3 (C-Ar); 
90.0, 80.5 (C-1´´, C-2´´); 72.1 (C-1); 62.7 (C-4); 55.1, 53.0 (C-3, C-1´); 39.4 (C-2); 30.9 (C-3´´); 24.1 
(C-2´); 22.0 (C-4´´); 19.1 (C-5´´); 13.7 (C-6´´); IR (ATR): 3288, 2927, 2869, 1452, 1354, 1087, 1059, 
1039, 838, 760, 700, 554 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C24H32NO2: 366.24276; found: 
366.24202. 
(1R,3R)-1-(5-Dec-1-ynyl-thiophen-2-yl)-3-((R)-1-phenylethylamino)-butane-1,4-diol (anti-
21Ca). This product was prepared according to the general procedure; compound anti-21Ca 
(334 mg, 78%) was obtained as an yellowish oil after purification by flash column 
chromatography, eluting with EtOAc/NH3 (100:1). TLC: Rf = 0.45 (EtOAc/NH3 100:1, UV, KMnO4); 
[]D
20 = + 27.1 (c 0.23, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.35-7.21 (m, 5H, H-Ar); 6.82 (d, 1H, 
J = 3.6 Hz, H-Het); 6.46 (d, 1H, J = 3.6 Hz, H-Het); 5.10-5.05 (m, 1H, H-1); 3.91 (q, 1H, J = 6.4 Hz, 
H-1´); 3.80 (dd, 1H, J = 4.1, 10.9 Hz, H-4A); 3.44 (dd, 1H, J = 3.6, 11.0 Hz, H-4B); 2.79-2.74 (m, 1H, 
H-3); 2.41 (t, 2H, J = 7.1 Hz, H-3´´); 2.10-2.00 (m, 1H, H-2A); 1.74 (ddd, 1H, J = 3.5, 5.8, 14.7 Hz, 
H-2B); 1.64-1.54 (m, 2H, H-4´´); 1.50-1.41 (m, 2H, H-5´´); 1.38 (d, 3H, J = 6.5 Hz, H-2´); 1.34-1.24 
(m, 8H, H-6´´-H-9´´); 0.89 (t, 3H, J = 6.7 Hz, H-10´´); 13C NMR (75 MHz, CDCl3):  = 149.9, 143.8, 
130.6, 128.7, 127.4, 127.0, 122.6, 122.5 (C-Ar, C-Het); 94.2, 73.9 (C-1´´, C-2´´); 69.1 (C-1); 62.6 (C-
4); 55.0, 53.0 (C-3, C-1´); 39.3 (C-2); 31.9 (C-3´´); 29.2 (C-4´´); 29.1 (C-5´´); 28.9 (C-6´´); 28.6 (C-
7´´); 24.4 (C-2´); 22.7 (C-8´´); 19.7 (C-9´´); 14.1 (C-10´´); IR (ATR): 3290, 2933, 2843, 1451, 1055, 
803, 755, 724, 701, 556 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C26H38NO2S: 428.26178; found: 
428.26149. 
(1R,3R)-1-(5-Hex-1-ynyl-thiophen-2-yl)-3-((R)-1-phenylethylamino)-butane-1,4-diol (anti-
21Cb). This product was prepared according to the general procedure; compound anti-21Cb 
(279 mg, 75%) was obtained as an yellowish oil after purification by flash column 
chromatography, eluting with CH2Cl2/acetone/NH3 (30:10:0.5). TLC: Rf = 0.45 
(CH2Cl2/acetone/NH3 30:10:0.5, UV, KMnO4); []D
20 = +25.7 (c 0.26, CHCl3); 
1H NMR (300 MHz, 
CDCl3):  = 7.35-7.20 (m, 5H, H-Ar); 6.83 (d, 1H, J = 3.6 Hz, H-Het); 6.45 (d, 1H, J = 3.6 Hz, H-Het); 
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5.09-5.03 (m, 1H, H-1); 3.90 (q, 1H, J = 6.5 Hz, H-1´); 3.79 (dd, 1H, J = 4.1, 10.9 Hz, H-4A); 3.43 
(dd, 1H, J = 3.5, 11.0 Hz, H-4B); 2.80-2.74 (m, 1H, H-3); 2.41 (t, 2H, J = 7.1 Hz, H-3´´); 2.04 (ddd, 
1H, J = 4.1, 9.2, 14.2 Hz, H-2A); 1.74 (ddd, 1H, J = 3.4, 5.7, 14.5 Hz, H-2B); 1.64-1.50 (m, 2H, H-
4´´); 1.50-1.41 (m, 2H, H-5´´); 1.36 (d, 3H, J = 6.5 Hz, H-2´); 0.94 (t, 3H, J = 6.7 Hz, H-6´´); 13C NMR 
(75 MHz, CDCl3):  = 149.9, 143.8, 130.6, 128.6, 127.4, 127.0, 122.6, 122.5 (C-Ar, C-Het); 94.1, 
73.9 (C-1´´, C-2´´); 69.2 (C-1); 62.6 (C-4); 55.0, 52.9 (C-3, C-1´); 39.3 (C-2); 30.7 (C-3´´); 24.4 (C-2´); 
22.0 (C-4´´); 19.4 (C-5´´); 13.6 (C-6´´); IR (ATR): 3277, 2935, 2844, 1450, 1151, 1098, 800, 760, 
699, 555 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C22H30NO2S: 372.19918; found: 372.19862. 
(1S,3R)-1-(3-Dec-1-ynyl-phenyl)-3-((R)-1-phenylethylamino)-butane-1,4-diol (syn-22Aa). This 
product was prepared according to the general procedure; compound syn-22Aa (278 mg, 66%) 
was obtained as a pale yellow oil after purification by flash column chromatography, eluting 
with CH2Cl2/acetone (7:1 up to 5:1). TLC: Rf = 0.31 (CH2Cl2/acetone 5:1, UV, KMnO4); []D
20 = 
+10.5 (c 0.19, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.43-7.17 (m, 9H, H-Ar); 4.64 (dd, 1H, J = 
1.7, 10.3 Hz, H-1); 4.02 (q, 1H, J = 6.6 Hz, H-1´); 3.82 (dd, 1H, J = 3.9, 11.0 Hz, H-4A); 3.42 (dd, 1H, 
J = 2.2, 11.0 Hz, H-4B); 2.780-2.73 (m, 1H, H-3); 2.38 (t, 2H, J = 7.0 Hz, H-3´´); 1.74 (td, 1H, J = 
10.7, 14.3 Hz, H-2A); 1.62-1.51 (m, 1H, H-2B, 2H, H-4´´); 1.50-1.36 (m, 2H, H-5´´); 1.39 (d, 3H, J = 
6.6 Hz, H-2´); 1.34-1.22 (m, 8H, H-6´´-H-9´´); 0.87 (t, 3H, J = 6.6 Hz, H-10´´); 13C NMR (75 MHz, 
CDCl3):  = 145.0, 144.0, 130.2, 128.8, 128.8, 128.1, 127.4, 127.0, 124.7, 123.9 (C-Ar); 90.2, 80.6 
(C-1´´, C-2´´); 74.1 (C-1); 62.2 (C-4); 55.9, 54.9 (C-3, C-1´); 41.3 (C-2); 31.8 (C-3´´); 29.2 (C-4´´); 
29.1 (C-5´´); 28.9 (C-6´´); 28.8 (C-7´´); 25.2 (C-2´); 22.7 (C-8´´); 19.4 (C-9´´); 14.1 (C-10´´); IR (ATR): 
3286, 2923, 2851, 1452, 1119, 1080, 1055, 795, 761, 698, 555 cm-1. HRMS (ESI): m/z [M + H]+ 
calcd for C28H40NO2: 422.30536; found: 422.30531. 
(1S,3R)-1-(3-Hex-1-ynyl-phenyl)-3-((R)-1-phenylethylamino)-butane-1,4-diol (syn-22Ab). This 
product was prepared according to the general procedure; compound syn-22Ab (281 mg, 77%) 
was obtained as a pale yellow oil after purification by flash column chromatography, eluting 
with CH2Cl2/acetone (8:1 up to 5:1). TLC: Rf = 0.33 (CH2Cl2/acetone 5:1, UV, KMnO4); []D
20 = 
+12.1 (c 0.55, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.43-7.16 (m, 9H, H-Ar); 4.66 (dd, 1H, J = 
1.6, 10.4 Hz, H-1); 4.04 (q, 1H, J = 6.6 Hz, H-1´); 3.84 (dd, 1H, J = 3.9, 10.9 Hz, H-4A); 3.42 (dd, 1H, 
J = 2.2, 11.0 Hz, H-4B); 2.83-2.75 (m, 1H, H-3); 2.40 (t, 2H, J = 7.0 Hz, H-3´´); 1.76 (td, 1H, J = 10.7, 
14.4 Hz, H-2A); 1.64-1.53 (m, 1H, H-2B, 2H, H-4´´); 1.53-1.44 (m, 2H, H-5´´); 1.42 (d, 3H, J = 6.6 
Hz, H-2´); 0.95 (t, 3H, J = 6.6 Hz, H-6´´); 13C NMR (75 MHz, CDCl3):  = 145.0, 144.0, 130.2, 128.9, 
128.8, 128.1, 127.5, 127.1, 124.8, 123.9 (C-Ar); 90.1, 80.7  (C-1´´, C-2´´); 74.1 (C-1); 62.3 (C-4); 
56.0, 54.9 (C-3, C-1´); 41.3 (C-2); 30.9 (C-3´´); 25.3 (C-2´); 22.0 (C-4´´); 19.1 (C-5´´); 13.7 (C-6´´); IR 
(ATR): 3278, 2943, 2855, 1444, 1198, 1126, 1045, 788, 755, 699, 556 cm-1. HRMS (ESI): m/z [M + 
H]+ calcd for C24H32NO2: 366.24276; found: 366.24275. 
(1S,3R)-1-(4-Dec-1-ynyl-phenyl)-3-((R)-1-phenylethylamino)-butane-1,4-diol (syn-22Ba). This 
product was prepared according to the general procedure; compound syn-22Ba (337 mg, 80%) 
was obtained as a pale yellow oil after purification by flash column chromatography, eluting 
with EtOAc/NH3 (100:1). TLC: Rf = 0.31 (EtOAc/NH3 100:1, UV, KMnO4); []D
20 = -7.6 (c 0.28, 
CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.42-7.19 (m, 9H, H-Ar); 4.65 (dd, 1H, J = 1.2, 9.9 Hz, H-1); 
4.04 (q, 1H, J = 6.6 Hz, H-1´); 3.82 (dd, 1H, J = 3.7, 11.0 Hz, H-4A); 3.42 (dd, 1H, J = 2.1, 11.1 Hz, 
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H-4B); 2.82-2.73 (m, 1H, H-3); 2.38 (t, 2H, J = 7.0 Hz, H-3´´); 1.81-1.65 (m, 1H, H-2A); 1.62-1.51 
(m, 1H, H-2B, 2H, H-4´´); 1.50-1.36 (m, 2H, H-5´´); 1.42 (d, 3H, J = 6.6 Hz, H-2´); 1.34-1.22 (m, 8H, 
H-6´´-H-9´´); 0.87 (t, 3H, J = 6.6 Hz, H-10´´); 13C NMR (75 MHz, CDCl3):  = 144.3, 143.8, 131.5, 
128.8, 127.5, 127.1, 125.4, 122.8 (C-Ar); 90.1, 80.5 (C-1´´, C-2´´); 74.2   (C-1); 62.2 (C-4); 56.0, 
55.0 (C-3, C-1´); 41.2 (C-2); 31.9 (C-3´´); 29.2 (C-4´´); 29.1 (C-5´´); 29.0 (C-6´´); 28.8 (C-7´´); 25.2 
(C-2´); 22.7 (C-8´´); 19.4 (C-9´´); 14.1 (C-10´´); IR (ATR): 3268, 2935, 2844, 1441, 1188, 1135, 
1040, 758, 702, 554 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C28H40NO2: 422.30536; found: 
422.30531. 
(1S,3R)-1-(4-Hex-1-ynyl-phenyl)-3-((R)-1-phenylethylamino)-butane-1,4-diol (syn-22Bb). This 
product was prepared according to the general procedure; compound syn-22Bb (219 mg, 60%) 
was obtained as a pale yellow oil after purification by flash column chromatography, eluting 
with EtOAc/NH3 (100:1). TLC: Rf = 0.30 (EtOAc/NH3 100:1, UV, KMnO4); []D
20 = -9.3 (c 0.38, 
CHCl3) (EtOAc:NH3 = 100:1, Rf = 0.30); 
1H NMR (300 MHz, CDCl3):  = 7.42-7.19 (m, 9H, H-Ar); 
4.66 (dd, 1H, J = 1.6, 10.4 Hz, H-1); 4.06 (q, 1H, J = 6.6 Hz, H-1´); 3.84 (dd, 1H, J = 3.9, 11.0 Hz, H-
4A); 3.42 (dd, 1H, J = 2.3, 11.1Hz, H-4B); 2.79 (tdd, 1H, J = 3.5, 6.7, 10.4 Hz, H-3); 2.40 (t, 2H, J = 
6.9 Hz, H-3´´); 1.84-1.73 (m, 1H, H-2A); 1.66-1.55 (m, 2H, H-4´´); 1.53-1.46 (m, 1H, H-2B); 1.42 (d, 
3H, J = 6.6 Hz, H-2´); 1.45-1.25 (m, 2H, H-5´´); 0.95 (t, 3H, J = 6.6 Hz, H-6´´); 13C NMR (75 MHz, 
CDCl3):  = 145.0, 144.0, 130.2, 128.9, 128.8, 128.1, 127.5, 127.1, 124.8, 123.9 (C-Ar); 90.1, 80.7 
(C-1´´, C-2´´); 74.1 (C-1); 62.3 (C-4); 56.0, 54.9 (C-3, C-1´); 41.3 (C-2); 30.9 (C-3´´); 25.3 (C-2´); 22.0 
(C-4´´); 19.1 (C-5´´); 13.7 (C-6´´); IR (ATR): 3277, 2947, 2853, 1444, 1189, 1122, 1033, 787, 745, 
698, 556 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C24H32NO2: 366.24276; found: 366.24273. 
(1S,3R)-1-(5-Dec-1-ynyl-thiophen-2-yl)-3-((R)-1-phenylethylamino)-butane-1,4-diol (syn-22Ca). 
This product was prepared according to the general procedure; compound syn-22Ca (312 mg, 
73%) was obtained as an yellowish oil after purification by flash column chromatography, 
eluting with EtOAc/NH3 (100:1). TLC: Rf = 0.38 (EtOAc/NH3 100:1, UV, KMnO4); []D
20 = +7.8 (c 
0.45, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.44-7.28 (m, 5H, H-Ar); 6.92 (d, 1H, J = 3.6 Hz, H-
Het); 6.66 (d, 1H, J = 3.6 Hz, H-Het); 4.87 (dd, 1H, J = 1.5, 10.4 Hz, H-1); 4.05 (q, 1H, J = 6.5 Hz, H-
1´); 3.84 (dd, 1H, J = 3.9, 11.0 Hz, H-4A); 3.46 (dd, 1H, J = 2.1, 11.0 Hz, H-4B); 2.81-2.76 (m, 1H, 
H-3); 2.41 (t, 2H, J = 7.1 Hz, H-3´´); 1.89 (td, 1H, J = 10.8, 14.2 Hz, H-2A); 1.74-1.66 (m, 1H, H-2B); 
1.64-1.54 (m, 2H, H-4´´); 1.47-1.37 (m, 2H, H-5´´); 1.41 (d, 3H, J = 6.5 Hz, H-2´); 1.34-1.25 (m, 8H, 
H-6´´-H-9´´); 0.89 (t, 3H, J = 6.7 Hz, H-10´´); 13C NMR (75 MHz, CDCl3):  = 149.7, 143.7, 130.6, 
128.9, 127.6, 127.1, 122.6, 122.0 (C-Ar, C-Het); 94.2, 74.0 (C-1´´, C-2´´); 70.9 (C-1); 62.1 (C-4); 
55.7, 55.0 (C-3, C-1´); 41.4 (C-2); 31.9 (C-3´´); 29.2 (C-4´´); 29.1 (C-5´´); 29.0 (C-6´´); 28.6 (C-7´´); 
25.1 (C-2´); 22.7 (C-8´´); 19.7 (C-9´´); 14.1 (C-10´´); IR (ATR): 3284, 2923, 2853, 1451, 1087, 1053, 
803, 761, 700, 557 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C26H38NO2S: 428.26178; found: 
428.26162. 
(1S,3R)-1-(5-Hex-1-ynyl-thiophen-2-yl)-3-((R)-1-phenylethylamino)-butane-1,4-diol (syn-22Cb). 
This product was prepared according to the general procedure; compound syn-22Cb (275 mg, 
74%) was obtained as an yellowish oil after purification by flash column chromatography, 
eluting with CH2Cl2/acetone/NH3 (50:10:0.5). TLC: Rf = 0.44 (CH2Cl2/acetone/NH3 50:10:0.5, UV, 
KMnO4); []D
20 = +10.4 (c 0.37, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.40-7.25 (m, 5H, H-Ar); 
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6.91 (d, 1H, J = 3.6 Hz, H-Het); 6.65 (d, 1H, J = 3.6 Hz, H-Het); 4.86 (dd, 1H, J = 1.6, 10.3 Hz, H-1); 
4.02 (q, 1H, J = 6.5 Hz, H-1´); 3.82 (dd, 1H, J = 3.9, 11.0 Hz, H-4A); 3.44 (dd, 1H, J = 2.2, 11.0 Hz, 
H-4B); 2.80-2.71 (m, 1H, H-3); 2.41 (t, 2H, J = 7.1 Hz, H-3´´); 1.86 (td, 1H, J = 10.7, 14.2 Hz, H-2A); 
1.72-1.65 (m, 1H, H-2B); 1.64-1.54 (m, 2H, H-4´´); 1.47-1.37 (m, 2H, H-5´´); 1.38 (d, 3H, J = 6.5 Hz, 
H-2´); 0.93 (t, 3H, J = 6.7 Hz, H-6´´); 13C NMR (75 MHz, CDCl3):  = 149.7, 143.8, 130.5, 128.8, 
127.5, 127.0, 122.5, 121.9 (C-Ar, C-Het); 94.1, 74.0 (C-1´´, C-2´´); 70.9 (C-1); 62.0 (C-4); 55.6, 54.9 
(C-3, C-1´); 41.5 (C-2); 30.7 (C-3´´); 25.2 (C-2´); 22.0 (C-4´´); 19.4 (C-5´´); 13.6 (C-6´´); IR (ATR): 
3327, 3284, 2928, 1451, 1356, 1052, 803, 761, 700, 556, 542 cm-1. HRMS (ESI): m/z [M + H]+ 
calcd for C22H30NO2S: 372.19918; found: 372.19814. 
General procedure for the tandem/one-pot triple bond CC hydrogenation, N-debenzylation 
and N-acylation 
The acetic acid (57 μL, 1 mmol) and subsequently 20 % Pd(OH)2/C (20 wt %) were added to the 
solution of anti-21A-C or syn-22A-C (0.5 mmol) in MeOH (25 mL). The reduction was carried out 
under 1.1 bar of H2 pressure at 40 °C. When the reduction was completed (monitoring TLC), 
MeOH was evaporated under reduced pressure. The residue was dissolved in THF (15 mL) and 
dodecanoic acid N-hydroxysuccinimide ester (X=C11H23CO2Su, 178 mg, 0.6 mmol) was added. 
The reaction mixture was stirred for the indicated time at room temperature. Solvent was 
evaporated under reduced pressure and the crude product was purified by flash column 
chromatography to yield the desired product 14. 
(1R,3R)-1-N-(3-(3-Decylphenyl)-3-hydroxy-1-hydroxymethyl)dodecanamide (anti-14Aa). This 
product was prepared according to the general procedure; compound anti-14Aa (212 mg, 84%) 
was obtained as an off-white solid after purification by flash column chromatography, eluting 
with hexane/EtOAc (1:1 up to 1:3). TLC: Rf = 0.35 (hexane/EtOAc 1:3, UV, KMnO4); Mp =  44-45 
°C (hexane/Et2O); []D
20 = +8.0 (c 0.9, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.27-7.12 (m, 3H, H-
Ar); 7.09-7.04 (m, 1H, H-Ar); 6.26 (d, 1H, J = 8.1 Hz, NH); 4.65 (dd, 1H, J = 2.7, 10.1 Hz, H-4´); 
4.28-4.22 (m, 1H, H-2´); 3.76 (dd, 1H, J = 3.7, 11.0 Hz, H-1´A); 3.70 (dd, 1H, J = 4.4, 11.0 Hz, H-
1´B); 2.58 (t, 2H, J = 7.5 Hz, H-1´´); 2.24 (t, 2H, J = 7.3 Hz, H-2); 1.95-1.55 (m, 2H, H-3´); 1.72-1.54 
(m, H-3, 2H, H-2´´); 1.40-1.18 (m, 16H, H-4-H-11, 14H, H-3´´-H-9´´); 0.87 (t, 6H, J = 7.0 Hz, H-12, 
H-10´´); 13C NMR (75 MHz, CDCl3):  = 174.9 (C-1); 143.8, 143.2, 128.3, 127.4, 125.6, 122.8 (C-
Ar); 70.6 (C-4´); 65.4 (C-1´); 48.9 (C-2´); 41.8 (C-3´); 36.8 (C-2); 36.1 (C-1´´); 31.9, 31.6, 29.7, 29.6, 
29.5, 29.5, 29.4, 29.4, 29.0, 25.8, 22.7, 14.1 (C-3-C-12, C-2´´-C-10´´); IR (ATR): 3560, 2915, 2848, 
1641, 1538, 1467, 1038, 1020, 705 cm-1. Anal. Calcd. For C32H57NO3: C 76.29, H 11.40, N 2.78. 
Found: C 76.54, H 11.53, N 2.80. 
(1R,3R)-1-N-(3-(3-Hexylphenyl)-3-hydroxy-1-hydroxymethyl)dodecanamide (anti-14Ab). This 
product was prepared according to the general procedure; compound anti-14Ab (137 mg, 61%) 
was obtained as an off-white solid after purification by flash column chromatography, eluting 
with hexane/EtOAc (1:1 up to 2:3). TLC: Rf = 0.28 (hexane/EtOAc 1:3, UV, KMnO4); Mp = 42-43 
°C (hexane/Et2O); []D
20 = +10.5 (c 0.86, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.27-7.12 (m, 3H, 
H-Ar); 7.09-7.04 (m, 1H, H-Ar); 6.28 (d, 1H, J = 8.1 Hz, NH); 4.65 (dd, 1H, J = 2.6, 10.1 Hz, H-4´); 
4.27-4.19 (m, 1H, H-2´); 3.75 (dd, 1H, J = 3.6, 11.0 Hz, H-1´A); 3.69 (dd, 1H, J = 4.3, 11.0 Hz, H-
1´B); 2.57 (t, 2H, J = 7.7 Hz, H-1´´); 2.23 (t, 2H, J = 7.3 Hz, H-2); 1.95-1.86 (m, 1H, H-3´A); 1.86-
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1.75 (m, 1H, H-3´B); 1.70-1.54 (m, 2H, H-3, 2H, H-2´´); 1.39-1.22 (m, 16H, H-4-H-11, 6H, H-3´´-H-
5´´); 0.88 (t, 6H, J = 7.0 Hz, H-12, H-6´´); 13C NMR (75 MHz, CDCl3):  = 174.9 (C-1); 143.8, 143.2, 
128.3, 127.4, 125.6, 122.8 (C-Ar); 70.6 (C-4´); 65.3 (C-1´); 48.9 (C-2´); 41.8 (C-3´); 36.8 (C-2); 36.1 
(C-1´´); 31.9, 31.7, 31.5, 29.6, 29.6, 29.5, 29.4, 29.3, 29.1, 25.8, 22.7, 22.6, 14.1, 14.1 (C-3-C-12, 
C-2´´-C-6´´); IR (ATR): 3566, 3332, 2914, 2849, 1644, 1520, 1466, 1046, 1027, 720, 702 cm-1. 
Anal. Calcd. For C28H49NO3: C 75.12, H 11.03, N 3.13. Found: C 75.07, H 11.14, N 3.06. 
(1R,3R)-1-N-(3-(4-Decylphenyl)-3-hydroxy-1-hydroxymethyl)dodecanamide (anti-14Ba). This 
product was prepared according to the general procedure; compound anti-14Ba (146 mg, 58%) 
was obtained as an off-white solid after purification by flash column chromatography, eluting 
with hexane/EtOAc (1:1 up to 1:3). TLC: Rf = 0.37 (hexane/EtOAc 1:3, UV, KMnO4); Mp = 88-89 
°C (hexane/Et2O); []D
20 = +11.9 (c 0.85, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.25 (d, 2H, J = 8.0 
Hz, H-Ar); 7.13 (d, 2H, J = 8.0 Hz, H-Ar); 6.27 (d, 1H, J = 8.0 Hz, NH); 4.65 (dd, 1H, J = 2.2, 10.3 Hz, 
H-4´); 4.26-4.20 (m, 1H, H-2´); 3.74 (dd, 1H, J = 3.4, 11.0 Hz, H-1´A); 3.69 (dd, 1H, J = 4.3, 11.0 Hz, 
H-1´B); 2.57 (t, 2H, J = 7.6 Hz, H-1´´); 2.22 (t, 2H, J = 7.5 Hz, H-2); 1.90 (ddd, 1H, J = 2.5, 10.1, 12.8 
Hz, H-3´A); 1.82 (ddd, 1H, J = 3.8, 10.4, 14.1 Hz, H-3´B); 1.68-1.61 (m, 2H, H-3); 1.61-1.55 (m, 2H, 
H-2´´); 1.35-1.20 (m, 16H, H-4-H-11, 14H, H-3´´-H-9´´); 0.87 (t, 6H, J = 7.0 Hz, H-12, H-10´´); 13C 
NMR (75 MHz, CDCl3):  = 174.9 (C-1); 142.1, 141.1, 128.5, 125.5 (C-Ar); 70.4 (C-4´); 65.4 (C-1´); 
49.0 (C-2´); 41.6 (C-3´); 36.8 (C-2); 35.6 (C-1´´); 31.9, 31.7, 31.4, 29.6, 29.5, 29.4, 29.3, 29.0, 25.9, 
22.7, 14.1 (C-3-C-12, C-2´´-C-10´´); IR (ATR): 3560, 2911, 2848, 1645, 1538, 1467, 1038, 1020, 
703 cm-1. Anal. Calcd. For C32H57NO3: C 76.29, H 11.40, N 2.78. Found: C 75.96, H 11.61, N 2.72. 
(1R,3R)-1-N-(3-(4-Hexylphenyl)-3-hydroxy-1-hydroxymethyl)dodecanamide (anti-14Bb). This 
product was prepared according to the general procedure; compound anti-14Bb (148 mg, 66%) 
was obtained as an off-white solid after purification by flash column chromatography, eluting 
with hexane/EtOAc (1:1 up to 1:3). TLC: Rf = 0.33 (hexane/EtOAc 1:3, UV, KMnO4); Mp = 63-64 
°C (hexane/Et2O); []D
20 = +8.1 (c 1,4, CHCl3) (hexane/EtOAc = 1:1 – 1:3, Rf = 0.33); 
1H NMR (600 
MHz, CDCl3):  = 7.25 (d, 2H, J = 8.0 Hz, H-Ar); 7.13 (d, 2H, J = 8.0 Hz, H-Ar); 6.29 (d, 1H, J = 7.9 
Hz, NH); 4.65 (dd, 1H, J = 2.3, 10.3 Hz, H-4´); 4.26-4.20 (m, 1H, H-2´); 3.74 (dd, 1H, J = 3.5, 11.0 
Hz, H-1´A); 3.69 (dd, 1H, J = 4.3, 11.0 Hz, H-1´B); 2.57 (t, 2H, J = 7.7 Hz, H-1´´); 2.22 (t, 2H, J = 7.3 
Hz, H-2); 1.89 (ddd, 1H, J = 2.6, 10.1, 12.9 Hz, H-3´A); 1.81 (ddd, 1H, J = 3.8, 10.4, 14.1 Hz, H-3´B); 
1.68-1.61 (m, 2H, H-3); 1.61-1.55 (m, 2H, H-2´´); 1.35-1.24 (m, 16H, H-4-H-11, 6H, H-3´´-H-5´´); 
0.88 (t, 6H, J = 7.0 Hz, H-12, H-6´´); 13C NMR (150 MHz, CDCl3):  = 174.8 (C-1); 142.1, 141.1, 
128.4, 125.5 (C-Ar); 70.4 (C-4´); 65.4 (C-1´); 49.0 (C-2´); 41.6 (C-3´); 36.7 (C-2); 35.6 (C-1´´); 31.9, 
31.7, 31.4, 29.6, 29.5, 29.3, 29.3, 29.3, 29.0, 25.8, 22.6, 22.6, 14.1, 14.0 (C-3-C-12, C-2´´-C-6´´); IR 
(ATR): 3558, 3292, 2919, 2851, 1640, 1615, 1517, 1044, 1027, 721, 580 cm-1. Anal. Calcd. For 
C28H49NO3: C 75.12, H 11.03, N 3.13. Found: C 74.69, H 11.33, N 3.26. HRMS (ESI): m/z [M + H]
+ 
calcd for C28H50NO3: 448.37852; found: 448.37807. 
(1R,3S)-1-N-(3-(3-Decylphenyl)-3-hydroxy-1-hydroxymethyl)dodecanamide (syn-14Aa). This 
product was prepared according to the general procedure; compound syn-14Aa (154 mg, 61%) 
was obtained as an off-white solid after purification by flash column chromatography, eluting 
with hexane/EtOAc (1:1 up to 1:2). TLC: Rf = 0.30 (hexane/EtOAc 1:2, UV, KMnO4); Mp = 50-52 
°C (hexane/Et2O);  []D
20 = -22.3 (c 0.98, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.28-7.21 (m, 1H, 
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H-Ar); 7.16-7.07 (m, 3H, H-Ar); 6.42 (d, 1H, J = 6.3 Hz, NH); 4.79 (dd, 1H, J = 2.7, 8.8 Hz, H-4´); 
4.12-4.02 (m, 1H, H-2´); 3.74-3.60 (m, 2H, H-1´); 2.58 (t, 2H, J = 7.7 Hz, H-1´´); 2.17 (t, 2H, J = 7.5 
Hz, H-2); 2.04 (ddd, 1H, J = 3.4, 5.3, 14.6 Hz, H-3´A); 1.94 (ddd, 1H, J = 7.1, 8.8, 14.7 Hz, H-3´B); 
1.63-1.52 (m, 2H, H-3, 2H, H-2´´); 1.37-1.22 (m, 16H, H-4-H-11, 14H, H-3´´-H-9´´); 0.88 (t, 6H, J = 
7.0 Hz, H-12, H-10´´); 13C NMR (75 MHz, CDCl3):  = 174.3 (C-1); 144.1, 143.5, 128.5, 127.9, 
125.5, 122.8 (C-Ar); 72.2 (C-4´); 65.9 (C-1´); 50.9 (C-2´); 40.5 (C-3´); 36.8 (C-2); 36.0 (C-1´´); 31.9, 
31.5, 29.6, 29.6, 29.5, 29.4, 29.3, 29.3, 29.3, 25.7, 22.7, 22.6, 14.1, (C-3-C-12, C-2´´-C-10´´); IR 
(ATR): 3332, 2913, 2849, 1638, 1528, 1470, 1271, 1010, 706 cm-1. Anal. Calcd. For C32H57NO3: C 
76.29, H 11.40, N 2.78. Found: C 76.65, H 11.49, N 2.74. 
(1R,3S)-1-N-(3-(3-Hexylphenyl)-3-hydroxy-1-hydroxymethyl)dodecanamide (syn-14Ab). This 
product was prepared according to the general procedure; compound syn-14Ab (135 mg, 60%) 
was obtained as a pale yellow oil after purification by flash column chromatography, eluting 
with hexane/EtOAc (1:1 up to 1:3). TLC: Rf = 0.33 (hexane/EtOAc 1:3, UV, KMnO4); []D
20 = -27 (c 
1.0, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.24-7.21 (m, 1H, H-Ar); 7.16-7.06 (m, 3H, H-Ar); 6.45 
(d, 1H, J = 6.5 Hz, NH); 4.78 (dd, 1H, J = 3.2, 9.0 Hz, H-4´); 4.10-4.01 (m, 1H, H-2´); 3.69 (dd, 1H, J 
= 3.6, 10.6 Hz, H-1´A); 3.64 (dd, 1H, J = 2.9, 10.6 Hz, H-1´B); 2.58 (t, 2H, J = 7.7 Hz, H-1´´); 2.17 (t, 
2H, J = 7.5 Hz, H-2); 2.04 (ddd, 1H, J = 3.4, 5.3, 14.6 Hz, H-3´A); 1.92 (ddd, 1H, J = 7.0, 8.9, 14.8 
Hz, H-3´B); 1.63-1.55 (m, 2H, H-3, 2H, H-2´´); 1.37-1.22 (m, 16H, H-4-H-11, 6H, H-3´´-H-5´´); 0.88 
(t, 6H, J = 7.0 Hz, H-12, H-6´´); 13C NMR (75 MHz, CDCl3):  = 174.3 (C-1); 144.1, 143.4, 128.5, 
127.8, 125.5, 122.8 (C-Ar); 72.2 (C-4´); 65.9 (C-1´); 50.8 (C-2´); 40.6 (C-3´); 36.8 (C-2); 36.0 (C-1´´); 
31.9, 31.7, 31.5, 29.6, 29.6, 29.5, 29.4, 29.3, 29.3, 29.1, 25.7, 22.7, 22.6, 14.1, 14.1 (C-3-C-12, C-
2´´-C-6´´); IR (ATR): 3299, 2918, 2850, 1641, 1546, 1467, 1415, 1057, 702, 653 cm-1. HRMS (ESI): 
m/z [M + H]+ calcd for C28H49NO3: 447.37124; found: 448.37817. 
(1R,3S)-1-N-(3-(4-Decylphenyl)-3-hydroxy-1-hydroxymethyl)dodecanamide (syn-14Ba). This 
product was prepared according to the general procedure; compound syn-14Ba (131 mg, 52%) 
was obtained as an off-white solid after purification by flash column chromatography, eluting 
with hexane/EtOAc (1:1 – 1:3). TLC: Rf = 0.36 (hexane/EtOAc 1:3, UV, KMnO4); Mp = 91-93 °C 
(hexane/Et2O);  []D
20 = -21.5 (c 0.76, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.25 (d, 2H, J = 8.0 
Hz, H-Ar); 7.13 (d, 2H, J = 8.0 Hz, H-Ar); 6.27 (d, 1H, J = 8.0 Hz, NH); 4.65 (dd, 1H, J = 2.5, 8.5 Hz, 
H-4´); 4.20-4.26 (m, 1H, H-2´); 3.74 (dd, 1H, J = 3.4, 11.0 Hz, H-1´A); 3.69 (dd, 1H, J = 4.3, 11.0 Hz, 
H-1´B); 2.57 (t, 2H, J = 7.6 Hz, H-1´´); 2.22 (t, 2H, J = 7.5 Hz, H-2); 1.90 (ddd, 1H, J = 2.5, 10.1, 12.8 
Hz, H-3´A); 1.82 (ddd, 1H, J = 3.8, 10.4, 14.1 Hz, H-3´B); 1.61-1.61 (m, 2H, H-3); 1.61-1.55 (m, 2H, 
H-2´´); 1.35-1.20 (m, 16H, H-4-H-11, 14H, H-3´´-H-9´´); 0.87 (t, 6H, J = 7.0 Hz, H-12, H-10´´); 13C 
NMR (75 MHz, CDCl3):  = 174.3 (C-1); 142.7, 141.4, 128.6, 125.5 (C-Ar); 72.0 (C-4´); 66.0 (C-1´); 
50.8 (C-2´); 40.5 (C-3´); 36.9 (C-2); 35.6 (C-1´´); 31.9, 31.5, 31.4, 29.6, 29.6, 29.5, 29.5, 29.4, 29.4, 
29.3, 25.7, 22.7, 14.1 (C-3-C-12, C-2´´-C-10´´); IR (ATR): 3292, 2916, 2848, 1642, 1548, 1468, 
1057, 1039, 720, 654 cm-1. Anal. Calcd. For C32H57NO3: C 76.29, H 11.40, N 2.78. Found: C 76.35, 
H 11.55, N 2.72. 
(1R,3S)-1-N-(3-(4-Hexylphenyl)-3-hydroxy-1-hydroxymethyl)dodecanamide (syn-14Bb). This 
product was prepared according to the general procedure; compound syn-14Bb (132 mg, 59%) 
was obtained as an off-white solid after purification by flash column chromatography, eluting 
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with hexane/EtOAc (1:1 – 1:3). TLC: Rf = 0.31 (hexane/EtOAc 1:3, UV, KMnO4); Mp =  91-93 °C 
(hexane/Et2O); []D
20 = -23.8 (c 0.59, CHCl3); 
1H NMR (600 MHz, CDCl3):  = 7.23 (d, 2H, J = 8.0 
Hz, H-Ar); 7.14 (d, 2H, J = 8.0 Hz, H-Ar); 6.46 (d, 1H, J = 5.6 Hz, NH); 4.78 (dd, 1H, J = 2.4, 8.6 Hz, 
H-4´); 4.03-4.08 (m, 1H, H-2´); 3.67 (dd, 1H, J = 4.5, 11.4 Hz, H-1´A); 3.64 (dd, 1H, J = 3.0, 11.3 Hz, 
H-1´B); 2.57 (t, 2H, J = 7.7 Hz, H-1´´); 2.16 (t, 2H, J = 7.5 Hz, H-2); 2.05-2.00 (m, 1H, H-3´A); 1.96-
1.90 (m, 1H, H-3´B); 1.63-1.55 (m, 2H, H-3, 2H, H-2´´); 1.35-1.20 (m, 16H, H-4-H-11, 6H, H-3´´-H-
5´´); 0.88 (t, 6H, J = 7.0 Hz, H-12, H-6´´); 13C NMR (150 MHz, CDCl3):  = 174.3 (C-1); 142.6, 141.4, 
128.6, 125.5 (C-Ar); 72.0 (C-4´); 65.9 (C-1´); 50.8 (C-2´); 40.6 (C-3´); 36.9 (C-2); 35.6 (C-1´´); 31.9, 
31.7, 31.5, 29.7, 29.6, 29.6, 29.4, 29.4, 29.3, 29.0, 25.8, 22.7, 22.6, 14.1, 14.1 (C-3-C-12, C-2´´-C-
6´´); IR (ATR): 3288, 2922, 2844, 1644, 1544, 1455, 1045, 1011, 721, 651 cm-1. HRMS (ESI): m/z 
[M + H]+ calcd for C28H50NO3: 448.37852; found: 448.37837. 
General procedure fot thiophene ring hydrodesulfurization (HDS) 
A solution of anti-21C or syn-22C (1 mmol) in methanol (15 mL) was added to stirred suspension 
of activated Raney-Ni (5 wt eq.) in MeOH (4 mL). The catalyst was prepared from 2 g of 
commercial Raney-Ni suspension (Merck) by slow addition of solid NaOH (3.6 g) at 100 °C during 
1 h with subsequent decantation with water (2 × 20 mL) and methanol (3 × 20 mL). The reaction 
mixture was stirred under atmosphere of hydrogen at room temperature for 24 h. After this 
time, the Raney-Ni was filtered off and washed with MeOH (3 × 10 mL). Solvent was removed 
under reduced pressure and the crude product was purified by flash column chromatography to 
yield the desired product anti-23C or syn-24C. 
(2R,4S)-2-((R)-1-Phenylethylamino)-octadecane-1,4-diol (anti-23a). This product was prepared 
according to the general procedure; compound anti-23a (292 mg, 72%) was obtained as a white 
solid after purification by flash column chromatography, eluting with CH2Cl2/acetone/NH3 
(30:10:0.5). TLC: Rf = 0.35 (CH2Cl2/acetone/NH3 30:10:0.5, KMnO4); Mp = 45-46 °C; []D
20 = +29 
(c 0.18, CHCl3); 
1H NMR (600 MHz, CDCl3):  = 7.36-7.31 (m, 4H, H-Ar); 7.28-7.24 (m, 1H, H-Ar); 
3.93 (q, 1H, J = 6.5 Hz, H-1´); 3.76 (dd, 1H, J = 4.1, 10.8 Hz, H-1A); 3.73-3.67 (m, 1H, H-4); 3.47 
(dd, 1H, J = 4.1, 10.8 Hz, H-1B); 2.80-2.75 (m, 1H, H-2); 1.66 (ddd, 1H, J = 2.8, 8.4, 14.1 Hz, H-3A); 
1.41-1.36 (m, 1H, H-3B); 1.37 (d, 3H, J = 6.6 Hz, H-2´); 1.34-1.14 (m, 26H, H-5-H-17); 0.87 (t, 3H, J 
= 6.6 Hz, H-18); 13C NMR (150 MHz, CDCl3):  = 144.6, 128.6, 127.3, 127.0 (C-Ar); 69.9 (C-4); 63.1 
(C-1); 55.3, 53.3 (C-2, C-1´); 37.7 (C-3); 37.2, 31.9, 29.7, 29.7, 29.7, 29.6, 29.4, 25.8, 22.7, 14.1 (C-
5-C-18); 24.3 (C-2´); IR (ATR): 3278, 2922, 2856, 1461, 1453, 1256, 1110, 1060, 761, 702, 548  
cm-1. Anal. Calcd. For C26H47NO2: C 76.98, H 11.68, N 3.45. Found: C 77.29, H 11.82, N 3.33. 
(2R,4S)-2-((R)-1-Phenylethylamino)-tetradecane-1,4-diol (anti-23b). This product was prepared 
according to the general procedure; compound anti-23b (255 mg, 73%) was obtained as 
a colorless oil after purification by flash column chromatography, eluting with 
CH2Cl2/acetone/NH3 (30:10:0.5). TLC: Rf = 0.40 (CH2Cl2/acetone/NH3 30:10:0.5, KMnO4); []D
20 = 
+28 (c 0.2, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.36-7.22 (m, 5H, H-Ar); 3.92 (q, 1H, J = 6.6 Hz, 
H-1´); 3.76 (dd, 1H, J = 4.3, 10.8 Hz, H-1A); 3.73-3.65 (m, 1H, H-4); 3.46 (dd, 1H, J = 4.1, 10.8 Hz, 
H-1B); 2.79-2.75 (m, 1H, H-2); 1.66 (ddd, 1H, J = 3.1, 8.5, 14.4 Hz, H-3A); 1.41-1.35 (m, 1H, H-3B); 
1.37 (d, 3H, J = 6.6 Hz, H-2´); 1.34-1.14 (m, 18H, H-5-H-13); 0.88 (t, 3H, J = 6.6 Hz, H-14); 13C NMR 
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(75 MHz, CDCl3):  = 144.7, 128.6, 127.3, 127.0 (C-Ar); 69.9 (C-4); 63.2 (C-1); 55.3, 53.3 (C-2, C-
1´); 37.9 (C-3); 37.2, 31.9, 29.7, 29.6, 29.4, 25.8, 22.7, 14.1 (C-5-C-14); 24.4 (C-2´); IR (ATR): 3288, 
2921, 2852, 1466, 1453, 1113, 1061, 760, 700, 551 cm-1. HRMS (ESI): m/z [M + H]+ calcd for 
C22H40NO2: 350.30536; found: 350.30485. 
(2R,4R)-2-((R)-1-Phenylethylamino)-octadecane-1,4-diol (syn-24a). This product was prepared 
according to the general procedure; compound syn-24a (207 mg, 51%) was obtained as a white 
solid after purification by flash column chromatography, eluting with CH2Cl2/acetone/NH3 
(20:10:0.3). TLC: Rf = 0.42 (CH2Cl2/acetone/NH3 20:10:0.3, KMnO4); Mp = 81-82 °C; []D
20 = 
+36.8 (c 0.75, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.36-7.22 (m, 5H, H-Ar); 4.00 (q, 1H, J = 6.5 
Hz, H-1´); 3.80 (dd, 1H, J = 4.0, 10.9 Hz, H-1A); 3.65-3.55 (m, 1H, H-4); 3.42 (dd, 1H, J = 2.3, 10.9 
Hz, H-1B); 2.67-2.58 (m, 1H, H-2); 1.52-1.16 (m, 3H, H-2´, 2H, H-3, 26H, H-5-H-17); 0.87 (t, 3H, J = 
6.6 Hz, H-18); 13C NMR (75 MHz, CDCl3):  = 144.3, 128.7, 127.3, 127.0 (C-Ar); 71.9 (C-4); 62.4 (C-
1); 55.7, 54.8 (C-2, C-1´); 38.7 (C-3); 38.1, 31.9, 29.7, 29.4, 25.4, 22.7, 14.1 (C-5-C-18); 25.4 (C-2´); 
IR (ATR): 3226, 2911, 2844, 1456, 1322, 1189, 1111, 1035, 821, 761, 699, 556 cm-1. Anal. Calcd. 
For C26H47NO2: C 76.98, H 11.68, N 3.45. Found: C 77.35, H 11.85, N 3.29. 
(2R,4R)-2-((R)-1-Phenylethylamino)-tetradecane-1,4-diol (syn-24b). This product was prepared 
according to the general procedure; compound syn-24b (217 mg, 62%) was obtained as 
a colorless oil after purification by flash column chromatography, eluting with 
CH2Cl2/acetone/NH3 (30:10:0.5). TLC: Rf = 0.38 (CH2Cl2/acetone/NH3 30:10:0.5, KMnO4); []D
20 = 
+37.0 (c 1.0, CHCl3); 
1H NMR (300 MHz, CDCl3):  = 7.36-7.24 (m, 5H, H-Ar); 4.02 (q, 1H, J = 6.5 
Hz, H-1´); 3.81 (dd, 1H, J = 4.0, 10.9 Hz, H-1A); 3.65-3.57 (m, 1H, H-4); 3.43 (dd, 1H, J = 2.2, 10.9 
Hz, H-1B); 2.67-2.59 (m, 1H, H-2); 1.52-1.42 (m, 1H, H-3A, 2H, H-5); 1.37 (d, 3H, J = 6.5 Hz, H-2´); 
1.34-1.22 (m, 1H, H-3B, 16H, H-6-H-13); 0.88 (t, 3H, J = 6.6 Hz, H-14); 13C NMR (75 MHz, CDCl3):  
= 144.2, 128.7, 127.3, 127.0 (C-Ar); 72.0 (C-4); 62.4 (C-1); 55.8, 54.8 (C-2, C-1´); 38.7 (C-3); 38.1, 
31.9, 29.8, 29.7, 29.4, 25.4, 22.7, 14.2 (C-5-C-14); 25.4 (C-2´); IR (ATR): 3236, 2917, 2899, 2847, 
1469, 1371, 1116, 1044, 820, 766, 701, 549 cm-1. HRMS (ESI): m/z [M + H]+ calcd for C22H40NO2: 
350.30536; found: 350.30480. 
General procedure for one-pot Pd-catalyzed N-debenzylation and acylation 
The acetic acid (2 eq.) and subsequently 20% Pd(OH)2/C (20 wt%) were added to the solution of 
aminodiols anti-23a,b or syn-24a,b (0.5 mmol) in methanol (50 mL). The reduction was carried 
out under 1.1 bar of H2 pressure at 40 °C. When the reduction was completed (monitoring TLC), 
methanol was evaporated under reduced pressure. The residue was dissolved in dry THF (10 
mL) and dodecanoic acid N-hydroxysuccinimide ester (X=C11H23CO2Su, 1.2 eq.) was added. 
Reaction mixture was stirred 1-2 days and was monitored by TLC. The solvent was removed 
under reduced pressure and the residue was purified by flash chromatography on silicagel to 
give HPA-12 or its analogues. 
(1R,3S)-1-N-(3-Hydroxy-1-hydroxymethyl-heptadecyl)dodecanamide (anti-15a). This product 
was prepared according to the general procedure; compound anti-15a (143 mg, 59%) was 
obtained as a white solid after purification by flash column chromatography, eluting with 




+5.7 (c 0.71, CHCl3); 
1H NMR (600 MHz, CDCl3/DMSO-d6 = 1/1):  = 6.57 (d, 1H, J = 7.2 Hz, NH); 
4.02-3.96 (m, 1H, H-2´); 3.56 (dd, 1H, J = 3.0, 11.1 Hz, H-1´A); 3.47 (dd, 1H, J = 4.0, 11.1 Hz, H-
1´B); 3.34-3.39 (m, 1H, H-4´); 2.09 (t, 2H, J = 7.5 Hz, H-2); 1.56-1.47 (m, 1H, H-3´A, 2H, H-3); 1.40-
1.33 (m, 1H, H-3´B); 1.31-1.10 (m, 16H, H-4-H-11, 26H, H-5´-H-17´); 0.75 (t, 6H, J = 6.6 Hz, H-12, 
H-18´); 13C NMR (150 MHz, CDCl3/DMSO-d6 = 1/1):  = 174.8 (C-1); 67.5 (C-4´); 64.9 (C-1´); 48.6 
(C-2´); 40.0 (C-3´); 37.1, 36.6, 31.9, 29.7, 29.7, 29.6, 29.6, 29.6, 29.5, 29.4, 29.3, 26.0, 25.9, 22.6, 
14.1 (C-2-C-12, C-5´-C-18´); IR (ATR): 3287, 2922, 2849, 1645, 1543, 1455, 1044, 1022, 720, 651 
cm-1. HRMS (ESI): m/z [M + H]+ calcd for C30H62NO3: 484.47242; found: 484.47233. 
(1R,3S)-1-N-(3-Hydroxy-1-hydroxymethyl-tridecyl)dodecanamide (anti-15b). This product was 
prepared according to the general procedure; compound anti-15b (114 mg, 53%) was obtained 
as a white solid after purification by flash column chromatography, eluting with hexane/EtOAc 
(1:1 up to 1:4). TLC: Rf = 0.35 (hexane/EtOAc 1:4, KMnO4); Mp = 88-90 °C; []D
20 = +7.5 (c 0.67, 
CHCl3); 
1H NMR (300 MHz, CDCl3):  = 6.20 (d, 1H, J = 8.3 Hz, NH); 4.23-4.11 (m, 1H, H-2´); 3.74 
(dd, 1H, J = 3.6, 10.9 Hz, H-1´A); 3.66 (dd, 1H, J = 4.3. 10.9 Hz, H-1´B); 3.58-3.48 (m, 1H, H-4´); 
2.22 (t, 2H, J = 7.6 Hz, H-2); 1.71-1.51 (m, 1H, H-3´A, 2H, H-4´); 1.52-1.38 (m, 1H, H-3´B, 2H, H-
5´); 1.33-1.15 (m, 16H, H-4-H-11, 16H, H-6´-H-13´); 0.87 (t, 6H, J = 6.6 Hz, H-12, H-14´); 13C NMR 
(75 MHz, CDCl3):  = 174.8 (C-1); 67.9 (C-4´); 65.5 (C-1´); 48.5 (C-2´); 39.7 (C-3´); 37.2, 36.8, 31.9, 
29.7, 29.7, 29.6, 29.4, 29.3, 26.0, 25.9, 22.7, 14.1 (C-2-C-12, C-5´-C-14´); IR (ATR): 3288, 2922, 
2835, 1646, 1549, 1455, 1155, 1022, 1011, 718, 651 cm-1. HRMS (ESI): m/z [M + H]+ calcd for 
C26H54NO3: 428.40982; found: 428.40941. 
 (1R,3R)-1-N-(3-Hydroxy-1-hydroxymethyl-heptadecyl)dodecanamide (syn-15a). This product 
was prepared according to the general procedure; compound syn-15a (145 mg, 60%) was 
obtained as a white solid after purification by flash column chromatography, eluting with 
hexane/EtOAc (1:1 up to 1:3). TLC: Rf = 0.31 (hexane/EtOAc 1:3, KMnO4); Mp = 85-86 °C; []D
20 = 
-3.9 (c 0.36, CHCl3); 
1H NMR (600 MHz, CDCl3):  = 6.45 (d, 1H, J = 6.5 Hz, NH); 4.06-4.01 (m, 1H, 
H-2´); 3.75-3.70 (m, 1H, H-4´); 3.69-3.63 (m, 2H, H-1´); 2.19 (t, 2H, J = 7.3 Hz, H-2); 1.87 (ddd, 1H, 
J = 2.0, 5.8, 14.6 Hz, H-3´A); 1.64-1.59 (m, 2H, H-3); 1.53 (ddd, 1H, J = 6.6, 9.4, 15.0 Hz, H-3´B); 
1.49-1.44 (m, 2H, H-5´); 1.41-1.35 (m, 2H, H-6´); 1.33-1.24 (m, 16H, H-4-H-11, 22H, H-7´-H-17´); 
0.88 (t, 6H, J = 6.6 Hz, H-12, H-18´); 13C NMR (150 MHz, CDCl3):  = 174.2 (C-1); 69.7 (C-4´); 65.9 
(C-1´); 50.7 (C-2´); 38.7 (C-3´); 38.2, 36.9, 31.9, 29.7, 29.7, 29.6, 29.6, 29.6, 29.5, 29.4, 29.3, 29.3, 
25.8, 25.5, 22.7, 14.1 (C-2-C-12, C-5´-C-18´); IR (ATR): 3287, 2922, 2844, 1652, 1548, 1455, 1131, 
1061, 728, 600 cm-1. Anal. Calcd. For C30H61NO3: C 74.48, H 12.71, N 2.90. Found: C 74.15, H 
12.59, N 2.95. 
(1R,3R)-1-N-(3-Hydroxy-1-hydroxymethyl-tridecyl)dodecanamide (syn-15b). This product was 
prepared according to the general procedure; compound syn-15b (129 mg, 60%) was obtained 
as a white solid after purification by flash column chromatography, eluting with hexane/EtOAc 
(1:2 up to 1:4). TLC: Rf = 0.34 (hexane/EtOAc 1:4, KMnO4); 60%;  Mp = 67-69 °C;  []D
20 = -6.1 (c 
1.0, CHCl3); 
1H NMR (600 MHz, CDCl3):  = 6.44 (d, 1H, J = 6.4 Hz, NH); 4.08-4.00 (m, 1H, H-2´); 
3.79-3.69 (m, 1H, H-4´); 3.69-3.61 (m, 2H, H-1´); 2.20 (t, 2H, J = 7.2 Hz, H-2); 1.89 (ddd, 1H, J = 
1.9, 5.7, 14.6 Hz, H-3´A); 1.70-1.40 (m, 1H, H-3´B, 2H, H-3, 2H, H-5´, 2H, H-6´); 1.39-1.20 (m, 16H, 
H-4-H-11, 14H, H-7´-H-13´); 0.88 (t, 6H, J = 6.6 Hz, H-12, H-14´); 13C NMR (150 MHz, CDCl3):  = 
SI-026 
 
174.1 (C-1); 69.8 (C-4´); 66.0 (C-1´); 50.8 (C-2´); 38.7 (C-3´); 38.2, 36.9, 31.9, 29.6, 29.6, 29.5, 
29.5, 29.3, 29.3, 25.8, 25.5, 22.7, 14.1 (C-2-C-12, C-5´-C-14´); IR (ATR): 3288, 2918, 2847, 1641, 
1561, 1468, 1132, 1066, 720, 601 cm-1. Anal. Calcd. For C26H53NO3: C 73.01, H 12.49, N 3.27. 
Found: C 72.79, H 12.63, N 3.22. 
General procedure for one-pot procedure exemplified by the preparation of  the product syn-
15a. 
 (1R,3R)-1-N-(3-Hydroxy-1-hydroxymethyl-heptadecyl)dodecanamide (syn-15a). A solution of 
(syn-22Ca, 0.491 mmol, 0.21 g) in methanol (8 mL) was added to stirred suspension of activated 
Raney-Ni (10 wt eq., 2.10 g) in MeOH (2 mL). The catalyst was prepared from 2 g of commercial 
Raney-Ni via the above described procedure. The reaction mixture was stirred under 
atmosphere of hydrogen at RT for 60 h. After this time, the Raney-Ni was filtered off and 
washed with MeOH (3 × 5 mL). Solvent was evaporated under reduced pressure. The residue 
was dissolved in THF (5 mL) and dodecanoic acid N-hydroxysuccinimide ester (X=C11H23CO2Su, 
0.588 mmol, 0.175 g, 1.2 eq.) was added. The reaction mixture was stirred at room temperature 
for 72 h. Solvent was evaporated under reduced pressure and the crude product was purified by 
flash column chromatography to yield the expected product syn-15a (0.086 g, 36%) as a white 
solid. Mp = 86-88 ºC; [α]D
20 = -3.9 (c 0.36, MeOH). All the other characteristics data are identical 






Human COL4A3ABP recombinant histidine-tagged protein fragment (START) (Product #ab95897) 
was obtained from Abcam. TALON® metal affinity resin was from Clontech. Fluorescence 
spectra were recorded with a Carey Eclipse spectrofluorometer equipped with a xenon lamp 
source and a Hamamatsu R928 photomultiplier tube. Fluorescent ceramide probe (N-((2S,3R,E)-
1,3-Dihydroxy-18-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)octadec-4-en-2-yl)palmitamide) 
was synthesized according to ref.1 
Fluorescence binding assays 1 
The His-tagged recombinant START domain of CERT protein (200 pmol, 6.5 mg, 13 µL of 
0.5mg/mL commercial solution) was dissolved in TBS (46 µL) in an Eppendorf tube. The HPA-12 
stereoisomer (200 pmol, 2 µL of 0.1 mM ethanolic solution) and TBS (30µL) was added to the 
tube and the mixture was incubated at 37 °C for 30 minutes. An equimolar amount of 
fluorescent ceramide probe (200pmol, 2 µL of 0.1mM ethanolic solution) was then added and 
after 30 minutes of incubation, the resulting complex was retained on a TALON® metal affinity 
resin (40 µL of 50% (v/v) preequilibrated with wash buffer), and incubated for 10 min at room 
                                                          
1
  S. Combemale, C. Santos, F. Rodriguez, V. Garcia, C. Galaup, C. Frongia, V. Lobjois, T. Levade, C. Baudoin-
Dehoux, S. Ballereau, Y. Genisson, RSC Advances, 2013, 3, 18970-18984. 
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temperature with rotary shaking. After centrifugation (14000 rpm, 30 s), the supernatant was 
collected as the “free fraction”. For washing, the resin was suspended in a 10mM imidazole 
solution in TBS (75 µL), and after centrifugation (14000 rpm, 30 s); the supernatant was 
collected as the “wash fraction 1”. This washing step was repeated to give the “wash fraction 2”. 
To liberate the protein bound fraction to the TALON® resin, the resin was suspended in a 
250mM imidazole solution in TBS (75 µL) and incubated for 5 minutes at room temperature. 
After centrifugation (14000 rpm, 30 s), the supernatant was collected as the “bound fraction”. A 
solution of chloroform/methanol (1:2 (v/v), 3.75-fold volume of each fraction) was then added 
to each collected fraction. Finally, to retrieve residual fluorophores non-specifically bound to the 
resin in the tube, TBS (85µL) and chloroform/methanol (1:2 (v/v), 375µL) were added to the 
resin in the tube, mixed, and centrifuged (14000rpm, 30s). The supernatant was collected as the 
“residual fraction”. For each fraction, the fluorescence was quantified with a Cary Eclipse 
spectrofluorimeter (NBD: excitation at 465 nm, emission at 530 nm). 
Ratio between the fluorescence intensity of this “bound fraction” and that of gathered washing 
fractions (“unbound fraction”) allows quantification of the probe binding to the START domain 
of CERT. Probe shifting results in a reduction of fluorescence intensity in this “bound fraction” in 
comparison to a blank experiment without competitor and compound binding was quantified by 
this percentage of fluorescence diminution. 
Results 
Binding assays of ceramide fluorescent probe to START domain in presence of ligand candidates 
AD754, AD762 and SynAnHPA-12. 
   
AD754 AD762 SynAnHPA-12 
 
 
Fluorescent probe (1R,3S)-HPA12 AD754 AD762 SynAnHPA-12 
% Unbound Fluo 55.8 87.4 85.8 75.9 90.9 
% Bound Fluo 44.2 12.6 14.2 24.1 9.1 
SD 0.9 4.5 2.8 3.1 0.6 
Fluo probe bound  
(% of control) 
- 28.5 32.2 54.6 20.6 
Table 1: Binding assays of a Cer fluorescent probe to START domain in the presence of competitors. 
The first line (% unbound Fluo) is the part of fluorescence in the “unbound fraction” in 
percentage, the second line (% bound fluo) is the part in percent of fluorescence in the “bound 
fraction”. Results are means from triplicate experiments and standard deviation (SD) is 
indicated. The last line is the probe fluorescence in the bound fraction as a percentage of the 
maximum value recorded in a control experiment without competitor. 
SI-028 
 
TR-FRET binding assay 2 
Materials 
Streptavidin-d2 conjugate (Product #610SADLA) and Europium cryptate-labeled anti-Histidine 
monoclonal antibody (Product #61HISKLA) were obtained from Cisbio Bioassays® (Codolet, 
France). Human COL4A3ABP recombinant histidine-tagged protein fragment (START) (Product 
#ab95897) was obtained from Abcam. Biotinylated ceramide probe (BioCer, or N-((2S,3R,E)-1,3-
dihydroxy-18-(5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)octadec-4-en-2-
yl)palmitamide) was synthesized according to ref.1 
HTRF assay 
8 µl of 5% of DMSO or compounds and a 1µM solution containing the START were incubated 30 
minutes at 37 °C. 2 µL of 1 µM Biotinylated ceramide solution was added in 384 Well Low 
Volume White Round Bottom Polystyrene NBS™ Microplate (Product #3673 from Corning®). 
After 30 minutes to 37 °C streptavidin-d2 and monoclonal anti-hist antibody labelled with 
Europium cryptate were added in detection buffer as recommended by manufacturer. After 15 
h of incubation at room temperature, the time-resolved fluorescence was measured using an 
Envision® plate reader (Perkin Elmer; ex = 320 nm, em = 590 and 665 nm; 60 µsec delay time). 
The donor fluorescence emission was measured at 590 nm instead of 620 nm in accordance 
with Envision apparatus and Cisbio recommendation. The HTRF readout was calculated as two 
wavelengths signal ratio: (665 nm/590 nm) x 104. FRET signal was defined as (HTRF compound 
ratio - HTRF negative ratio)/ HTRF blank ratio. HTRF negative ratio was (665 nm/590 nm) x 104 of 
well containing streptavidin-d2 and anti-Hist monoclonal antibody labelled with Europium 
cryptate. HTRF blank ratio was (665 nm/590 nm) x 104 of well containing anti-Hist monoclonal 
antibody labelled with Europium cryptate. 
Data handling 
Positive FRET signals were performed by dispensing DMSO 5%, so no inhibition of interaction 
was done. This maximal signal value obtained was set to 0 % inhibition.  
Percentage of inhibition was calculated using eq. 1:  
 
% inhib. = 100-(100* FRET signal compound) x FRET signal without compound ratio. 
The Z’ factor was calculated according to Zhang et al.3 with at least 32 assays for each control: 
            eq. 1 
All curves fits of sigmoïdal dose-response curves were performed with Prism 3.0 (Graphpad 
Software, San Diego, CA). 
EC50 determination by TR-FRET  
                                                          
2
  L. Fleury, C. Faux, C. Santos, S. Ballereau, Y. Génisson, F. Ausseil, J. Biomol. Screen., 2015, 20, 779-787. 
3
  Zhang, J. H.; Chung, T. D.; Oldenburg, K. R. J. Biomol. Screen. 1999, 4, 67-73. 
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The data obtained from the doses curve responses for HPA analogues were treated with Prism 
3.0 (Graphpad Software, San Diego, CA). Curve fits of sigmoïdal dose-response curves allowed 
the determination of EC50 for each analog. 
Compound EC50 (M) EC50 (nM) R
2
 
Syn-HPA-12 4.10E-06 4100 0.9897 
Anti-HPA-12 2.25E-05 22500 0.9899 
Syn-14Aa 3.24E-08 32.4 0.9571 
Anti-14Aa 6.74E-07 674 0.9607 
Syn-14Ab 1.49E-09 1.49 0.9868 
Anti-14Ab 1.23E-07 123 0.9773 
Syn-14Ba 4.18E-08 41.8 0.9175 
Anti-14Ba 7.28E-07 728 0.7654 
Syn-14Bb 8.49E-08 84.9 0.9334 
Anti-14Bb 3.17E-07 317 0.9426 
Syn-15b 6.32E-08 63.2 0.9825 
Anti-15b 1.18E-07 118 0.9874 
Table-2: EC50 and R squared values for HPA analogs determined by TR-FRET.  
Molecular graphics, molecular docking 
Molecular graphics and structural studies 
Protein molecular structures were generated using UCSF Chimera 1.8.1, UCSF Chimera is 
developed by the Resource for Biocomputing, Visualization, and Informatics at the University of 
California, San Francisco (supported by the NIGMS P41-GM103311). Protein structure used in 
this paper (2E3P) was structurally aligned with structure 2E3N set as reference using UCSF 
Chimera/Matchmaker. 
The protein structures in the reference space (2E3N) were prepared (structures check, 
rotamers, hydrogenation) using Accelrys Discovery Studio Visualizer (Accelrys Software Inc., 
Discovery Studio Modeling Environment, Release 4.0, San Diego: Accelrys Software Inc., 2013, 
http://accelrys.com/) and UCSF Chimera.  
The new ligand structures were sketched using ChemAxon Marvin 5.3.2 (2010, ChemAxon, 
http://www.chemaxon.com). The co-crystallized ligand structures were extracted from protein 
structures using SciTE text editor and Accelrys Discovery Studio Visualizer. The ligands were 
prepared (hybridization, hydrogenation, some geometry optimizations, 3D sketching) and 
aligned (center of mass) with co-crystallized ligands in the previously defined reference space 
using Discovery Studio Visualizer (DSV). The ligands were merged in libraries encoded with 
various chemical or tabular formats using DSV or in-house software. The libraries were checked 
using ChemAxon Marvin and eventually corrected using previous cited software. 
Docking protocols 
Molecular modelling (docking, scoring) was carried with Molegro Virtual Docker 6 (MVD) 
software (http://www.clcbio.com). 
The structure 2E3P (chain A: 2E3Pa) was chosen for molecular docking with a search space of 15 
Å radius (centered in the CERT binding cavity). 
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Ligands and residues of binding pocket were set flexible. According to the structural study, 42 
residues were defined for flexible docking: ALA 475, ALA 572, ALA 521, ALA 555, ALA 563, ARG 
442, ARG 471, ARG 478, ARG 574, ASN 504, GLN 467, GLN 477, GLU 446, GLU 575, HIS 469, ILE 
449, ILE 465, ILE 523, LEU 568, LYS 470, LYS 578, PHE 436, PHE 579, PRO 474, PRO 559, PRO 564, 
SER 476, THR 447, THR 448, THR 468, TRP 445, TRP 473, TRP 562, TYR 482, TYR 553, TYR 576, 
VAL 472, VAL 480, VAL 525, VAL 557, VAL 567, VAL 571. A tolerance of 0.99, a flexibility of 0.90 
and softened potentials were used during docking. Values of 2000 steps (lateral chains of 
residues) and 2000 steps (backbone) were used for final minimization (default values).  
No water molecules were taken in account in the paper.  
Moldock4was used as search function with a grid resolution of 0.20 Å. Moldock SE was used as 
docking optimizer with a population size of 200 (other parameters set as default) and 5000 
steps of calculation by run. Tabu clustering was used in order to rank the poses. For each ligand, 
a set of 20 poses per run was generated, using a RMSD threshold of 2.0 Å and Energy penalty of 
100 (default values) as clustering parameters.  
A template model was used5 with a grid resolution of 0.20 Å and a strength of 500 (default 
value). This template model was derived from structural studies. Polar heads of ceramides/HPAs 
have very similar conformations and positions in CERT's binding pocket; this is also the case for 
the overall trajectory of hydrophobic chains (structural alignments of CERT’s protein structures 
in the reference space).  
Using these structural data, template centers were defined on a basis of structurally aligned 
atoms of same chemical features. Then, 3 similarity groups were defined: (i) a steric group of 19 
atoms (1.8 Å radius, strength = 0.5); (ii) a hydrogen donor group of 3 atoms (1.8 Å radius, 










Figure 1 – Definition of docking templates 
                                                          
4
  R. Thomsen, M.H. Christensen. J. Med. Chem. 2006, 49, 3315-3321. 
5
  C. Santos, F. Rogriguez, V. Garcia, D. Berkeš, A. Daïch, L. Levade, C. Baudoin-Dehoux, S. Ballereau, Y. Génisson, 
ChemBioChem 2014, 15, 2522-2528. 
 




Docking poses were analyzed using Molegro Virtual Docker and Molegro Data Modeler software 
(MDM).  
After docking, the results issued from various protocols and docking templates were not merged 
and all poses were checked individually using MVD/MDM features.  
A filter was then applied on these ensembles, using 3 rules: i) A set of descriptors (Moldock, 
Rerank) was chosen, and the poses corresponding to the 10 best values, for each descriptor, 
were retained, giving a 10 desc ensemble by descriptor. ii) In each 10 desc ensemble, the so 
called ‘conform’ poses were selected.  
A ‘conform’ pose is defined by superposition of some ligands groups of polar head with their 
counterparts of ceramide/HPA-13. Ligand groups checked were: amide group, primary and 
secondary alcohols groups. iii) The pose which exhibits the maximum number of best values of 
descriptors, was retained for further analysis. 
For the best poses of each compound, some descriptors issued from docking protocol are 
reported in following table. 
 
Name Moldock Score HBond Rerank Score LE1 LE3 MW Heavy Atoms 
Syn-HPA-12 -149.681 -15.1339 -115.417 -5.75695 -4.43913 363.534 26 
Anti-HPA-12 -153.891 -10.3748 -121.602 -5.91887 -4.67702 363.534 26 
Syn-14Aa -190.276 -12.5 -132.213 -5.28544 -3.67257 503.8 36 
Anti-14Aa -199.257 -11.5942 -152.717 -5.5349 -4.24214 503.8 36 
Syn-14Ab -188.581 -14.6496 -141.576 -5.89317 -4.42425 447.694 32 
Anti-14Ab -170.583 -9,07174 -116.255 -5.33072 -3.63296 447.694 32 
Syn-14Ba -207.049 -10.1426 -156.418 -5.75135 -4.34493 503.8 36 
Anti-14Ba -188.569 -9.65318 -142.99 -5.23802 -3.97193 503.8 36 
Syn-14Bb -190.935 -15.7128 -139.07 -5.9667 -4.34593 447.694 32 
Anti-14Bb -164.538 -9.07403 -124.072 -5.14182 -3.87725 447.694 32 
Syn-15b -164.641 -18.4239 -122.279 -5.48803 -4.07597 427.704 30 
Anti-15b -180.658 -10.7279 -135.015 -6.02192 -4.5005 427.704 30 
Table 3: Docking data 
The values are given for best docking poses of compounds used in this study.  
MW is the molecular weight and Heavy atoms count is the number of heavy atoms (C, N, O) of 
each ligand. The other scores (Moldock, HBond, LE1, LE3, Rerank) are values obtained after 
docking and final minimization. The Moldock score (arbitrary units) is a value related to the total 
Energy. The Rerank score (arbitrary units) is a different weighting of terms included Moldock 
equation. HBond (arbitrary units) is a value related Hydrogen bonding energy. The values of LE1 





Superposition of the three calculated best poses of compound Anti-14Ab 
 
Superposition of the three calculated best poses of compound Syn-14Ab 
 
Primary cells cytotoxicity for compounds HPA-12 and Syn-14Ab 



























Legend : Primary cells cytotoxicity: human fibroblastes cells were obtained from donation of Thierry 
Levade’s laboratory (CRCT, Toulouse, France) and cultivated in DMEM medium (Gibco® GlutaMAX™, 
ThermoFisher, France) containing l-D-glutamine and supplemented with 10 % of fetal calf serum (Lonza, 
France), at 37 °C and under 5 % CO2. Cells (2×10
4) were seeded at day 0 in a 96-well plate. Solutions of 
test compound, stored at −20 °C as a 10−2 M stock solution in 100 % DMSO, were freshly prepared by 
dilution on day 1 in DMEM medium. Cells were treated in triplicate with test compound solutions at a 
dose range from 4.7 nM to 10 μM. Cell viability was assessed using the ATPLite kit (ATPlite 1step 
Luminescence Assay System, ref: 3016739, PerkinElmer), following the manufacturer′s instructions at 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































AD-519 (16C) HESI/HRMS positive
[M+H]+ = 382.01050   calcd. 382.01070
AD_519(16C)_160128-01 #1-8 RT: 0.00-0.26 AV: 8 NL: 1.73E8
T: FTMS + p ESI Full ms [50.00-2000.00]

















































AD 1182 (cis 18A) HESI/HRMS positive
[M+H]+ = 360.05927 calcd. 360.05937
AD_1182(cis18A)_160128-02 #1-9 RT: 0.01-0.29 AV: 9 NL: 1.05E8
T: FTMS + p ESI Full ms [50.00-2000.00]



















































[M+H]+ = 362.21147  calcd. 362.21146
AD_1258_(20Bb)_160201-03 #1-5 RT: 0.01-0.15 AV: 5 NL: 1.41E7
T: FTMS + p ESI Full ms [50.00-2000.00]















































AD 1232 (cis 20Cb) HESI/HRMS positive
[M+H]+ = 368.16765 calcd. 366.16788
AD_1232(cis20Cb)_160128-04 #14-19 RT: 0.47-0.65 AV: 6 NL: 1.78E7
T: FTMS + p ESI Full ms [50.00-2000.00]

















































[M+H]+ = 412.19075   calcd. 412.19072
AD_1412_(20Ae)_160201-04 #1-4 RT: 0.00-0.16 AV: 4 NL: 1.33E6
T: FTMS + p ESI Full ms [50.00-2000.00]
















































AD 1322 (cis 20Ce) HESI/HRMS positive
[M+H]+ = 418.14718 calcd. 418.14714
AD_1322cis20Ce)_160128-06 #3-14 RT: 0.08-0.47 AV: 12 NL: 4.20E7
T: FTMS + p ESI Full ms [50.00-2000.00]















































AD 1254 (trans19Ad) HESI/HRMS positive
[M+H]+ = 382.18003 calcd. 382.18016
AD_1254(trans19Ad)_160128-07 #19-22 RT: 0.65-0.76 AV: 4 NL: 2.61E6
T: FTMS + p ESI Full ms [50.00-2000.00]














































AD 1261 (trans19Ba) HESI/HRMS positive
[M+H]+ = 418.27370 calcd. 418.27406
AD_1261(trans19Ba)_160128-08 #19-23 RT: 0.75-0.89 AV: 5 NL: 1.98E6
T: FTMS + p ESI Full ms [50.00-2000.00]















































AD 1245 (trans19Cc) HESI/HRMS positive
[M+H]+ = 368.16780  calcd. 368.16788
AD_1245(trans19Cc)_160128-10 #4-10 RT: 0.11-0.36 AV: 7 NL: 2.00E6
T: FTMS + p ESI Full ms [50.00-2000.00]














































AD 1249 (transCd) HESI/HRMS positive
[M+H]+ = 388.13640  calcd. 388.13658
AD_1249(transCd)_160128-11 #2-19 RT: 0.04-0.71 AV: 18 NL: 3.88E6
T: FTMS + p ESI Full ms [50.00-2000.00]



















































AD 1393 (trans19Ce) HESI/HRMS positive
[M+H]+ = 418.14719 calcd. 418.14714
AD_1393trans19Ce)_160128-06 #3-14 RT: 0.08-0.47 AV: 12 NL:
4.20E7 T: FTMS + p ESI Full ms [50.00-2000.00]















































AD 1285 (anti14Bb) HESI/HRMS positive
[M+H]+ = 448.37807 calcd.  448.37852
[M+Na]+ = 470.35994
AD_1285(anti14Bb)_160128-12 #3-21 RT: 0.08-0.86 AV: 19 NL: 9.68E5
T: FTMS + p ESI Full ms [50.00-2000.00]
















































AD 1286 (syn14Bb) HESI/HRMS positive
[M+H]+ = 448.37837 calcd. 448.37852
[M+Na]+ = 470.36026
AD_1286(syn14Bb)_160128-09 #3-16 RT: 0.08-0.59 AV: 14 NL: 3.74E6
T: FTMS + p ESI Full ms [50.00-2000.00]

















































AD 1286 (anti15b) HESI/HRMS positive
[M+H]+ = 428.40941  calcd. 428.40982
[M+Na]+ = 450.39126
AD_1406(anti15b)_160128-13 #2-26 RT: 0.04-0.96 AV: 25 NL: 3.03E6
T: FTMS + p ESI Full ms [50.00-2000.00]
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